

PATENT APPLICATION TRANSMITTAL LETTER

PATENT GROUP
FOLEY, HOAG & ELIOT LLP
ONE POST OFFICE SQUARE
BOSTON, MA 02109-2170Atty Docket No. APV-007.01
A/S

To the Assistant Commissioner for Patents:

Transmitted herewith for filing under 35 U.S.C. 111 and 37 CFR 1.53 is the patent application of:

Stuart L. SCHREIBER; Peter J. BELSHAW; and Gerald CRABTREEentitled Gene Therapy by Cell Specific Targeting

Enclosed are:

(X) 80 pages of written description, claims and abstract.

(X) 4 sheets of drawings.

() an assignment of the invention to _____.

() executed declaration of the inventors.

() a certified copy of a _____ application.

() a verified statement to establish small entity status under 37 CFR 1.9 and 1.27.

(X) other: unexecuted Declaration, Petition and Power of Attorney.

CLAIMS AS FILED

	# FILED	# EXTRA	Rate	FEE	Rate (Small Entity)	FEE
BASIC FEE			\$770		\$385	
TOTAL CLAIMS	-20 =		x \$22		x \$11	
INDEPENDENT CLAIMS	-3 =	*	x \$80		x \$40	
MULTIPLE DEPENDENT CLAIMS			\$260		\$130	
* NUMBER EXTRA MUST BE ZERO OR LARGER			TOTAL			\$

() A check in the amount of \$ _____ to cover the filing fee is enclosed.

() The Commissioner is hereby authorized to charge and credit Deposit Account No. 06-1448 as described below. A duplicate copy of this sheet is enclosed.

() Charge the amount of \$ _____ as filing fee.

() Credit any overpayment.

() Charge any additional filing fees required under 37 CFR 1.16 and 1.17.

Certificate of Express Mail

Express Mail Label: EM 528 937 135 US

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, postage prepaid, "Post Office to Addressee", in an envelope addressed to the Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on this date of August 27, 1997.

August 27, 1997

Date of Deposit

Matthew P. VincentMatthew P. Vincent, Ph.D.
Reg. No. 36,709
Attorney for Applicants

Declaration, Petition and Power of Attorney For Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled:

GENE THERAPY BY CELL SPECIFIC TARGETING

the specification of which is filed herewith in the U.S. Patent and Trademark Office.

I do not know and do not believe that the subject matter of this application was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to the date of this application, and that said subject matter has not been patented or made the subject of an issued inventor's certificate in any country foreign to the United States on an application filed by me or my legal representatives or assigns more than twelve months prior to the date of this application; that I acknowledge my duty to disclose information of which I am aware which is material to the examination of this application, that no application for patent or inventor's certificate on the subject matter of this application has been filed by me or my representatives or assigns in any country foreign to the United States, except those identified below, and that I have reviewed and understand the contents of the specification, including the claims as amended by any amendment referred to herein.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

Check one: no such applications have been filed.
 such applications have been filed as follows

**EARLIEST FOREIGN APPLICATION(S), IF ANY FILED WITHIN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION**

Country	Application Number	Date of Filing (month,day,year)	Priority Claimed Under 35 USC 119
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)

I hereby claim the benefit under Title 35, United States Code, §120 or §119(e) of any United States application(s) and/or provisional application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application. As to subject matter of this application which is common to my earlier United States application, if any, described below, I do not believe that the same was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to said earlier application, or in public use or on sale in the United States more than one year prior to said earlier application, that the said common subject matter has not been patented or made the subject of an inventor's certificate issued before the date of said earlier application in any country foreign to the United States on an application, filed by me or my legal representatives or assigns more than twelve months prior to said application and that no application for patent or inventor's certificate on said subject matter has been filed by me or my representatives or assigns in any country foreign to the United States except those identified herein.

<u>60/024,484</u> (Application Serial No.)	<u>27 August 1996</u> (Filing Date)	<u>PENDING</u> (Status) (patented, pending, aband.)
 (Application Serial No.)	 (Filing Date)	 (Status) (patented, pending, aband.)
 (Application Serial No.)	 (Filing Date)	 (Status) (patented, pending, aband.)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Donald W. Muirhead	Reg. No. 33,978	Charles H. Cella	Reg. No. 38,099
Beth E. Arnold	Reg. No. 35,430	John C. Gorecki	Reg. No. 38,741
Matthew P. Vincent	Reg. No. 36,709	Edward J. Kelly	Reg. No. 38,936
		Sayoko Blodgett-Ford	Reg. No. 40,516

Send Correspondence to: Patent Group
Foley, Hoag & Eliot LLP
One Post Office Square
Boston, MA 02109

Direct Telephone Calls to: Matthew P. Vincent, Ph.D. (617) 832-1000

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor <u>Stuart L. SCHREIBER</u>	
Inventor's signature	Date
Residence <u>434 Marlborough Street, Boston, MA 02115</u>	
Citizenship <u>USA</u>	
Post Office Address (if different)	

Full name of second inventor Peter J. BELSHAW	
Inventor's signature	Date
Residence 41 Lewis Street, No. 1, Somerville, MA 02143	
Citizenship USA	
Post Office Address (if different)	

Full name of third inventor Gerald CRABTREE	
Inventor's signature	Date
Residence 7 Durham Road, Woodside, CA 94062	
Citizenship USA	
Post Office Address (if different)	

GENE THERAPY BY CELL SPECIFIC TARGETING**BACKGROUND OF THE INVENTION**

5 Tolerance to self major histocompatibility (MHC) antigens occurs during T cell maturation in the thymus. During ontogeny, exposure of the immune system to MHC antigens results in the loss of reactivity to those antigens, thus leaving the animal specifically tolerant into adult life. Inducing tolerance in adult animals has been accomplished by high-dose cytoreductive therapy and bone marrow transplantation.

10 Bone marrow transplantation has been found to be effective in the control of certain malignant lymphohematopoietic diseases where conventional chemotherapy has failed or would be expected to fail. There are attendant disadvantages to bone marrow transplantation. Often there is an allogeneic antitumor effect independent of the chemoradiotherapy of the preparative regimen. This adoptive immunotherapy effect is, in large measure, accompanied by graft-versus-host (GVH) disease.

15 Historically, GVH disease has been a major cause of serious morbidity and death after bone marrow transplantation. Graft-versus-host disease and its treatment are accompanied by profound immunodeficiency and immune dysregulation, which places the patient at risk for life-threatening infections and other complications. GVH disease has accounted for approximately two thirds of the deaths after allogeneic bone marrow transplantation.

20 Removing T lymphocytes in allogeneic bone marrow inocula to prevent GVH disease is associated with increased rates of engraftment failure. While these drawbacks are generally considered acceptable for the treatment of otherwise lethal malignant diseases, they would severely limit the application of MHC mismatched bone marrow transplantation as a preparative regimen for organ transplantation, in which nonspecific immunosuppressive agents, while not without major complications, are effective.

25 Since GVH disease is immunologically mediated, efforts to prevent its development have involved the use of immunosuppressive therapy. Of the many agents studied, methotrexate, glucocorticoids, and cyclosporin have been found to be useful. It is a continuing goal to develop better treatments for patients in need of a bone marrow transplant or other diseases that can be specifically cell targeted.

SUMMARY OF THE INVENTION

One one embodiment of the present invention provides a method for selectively inhibiting proliferation of a hematopoietic cell by contacting a cell which ectopically expresses a mutated macrolide binding protein (MBP) with a macrolide which selectively induces macrolide-dependent inhibition of proliferation of cells expressing the mutated 5 MBP compared to cells expressing a wild-type form of the MBP. In such embodiments, the mutated MBP has an altered macrolide-binding specificity relative to the wild-type form MBP, e.g., which provides the specificity for macrolide-dependent inhibition.

In another embodiment, the invention provides a method for selectively inhibiting proliferation of a hematopoietic cell comprising: (i) causing, in the cell, the ectopic 10 expression of an MBP gene encoding a mutated macrolide binding protein (MBP) having an altered macrolide-binding specificity relative to a wild-type form of the MBP, which mutated MBP retains the ability to cause macrolide-dependent inhibition of proliferation; and (ii) contacting the cell with a macrolide which selectively binds to the altered MBP 15 relative to the wild-type MBP and selectively induces macrolide-dependent inhibition of proliferation of cells expressing the mutated MBP relative to cells not expressing only the wild-type MBP.

In yet another embodiment, there is provided a method for selectively inhibiting proliferation of a transplanted hematopoietic cell by the steps of (i) transplanting, into an animal, hematopoietic cells which ectopically expresses a MBP gene encoding a mutated 20 macrolide binding protein (MBP), the mutated MBP having an altered macrolide-binding specificity relative to the wild-type form MBP; and (ii) administering to the animal an amount of a macrolide sufficient to inhibit proliferation of the transplanted cells, which macrolide selectively induces macrolide-dependent inhibition of proliferation of cells expressing the mutated MBP compared to cells expressing a wild-type form of the MBP.

25 In still another embodiment, the there is provides a method for treating graft-versus-host disease in an animal by selectively inhibiting proliferation of hematopoietic cells contained a transplanted tissue. Such methods are particularly useful in the transplantation of bone marrow or hematopoeitic stem cells. The method generally comprises transducing, e.g., before implantation, at least a sub-population of 30 hematopoietic cells of the transplanted tissue with a gene for ectopic expression of a mutated macrolide binding protein (MBP), the mutated MBP having an altered macrolide-binding specificity relative to the wild-type form MBP. Prior to, concurrent with and/or subsequent to transplanting the tissue, the animal (or cells in culture) are treat with an amount of a macrolide sufficient to inhibit proliferation of the hematopoeitic transplanted 35 cells, which macrolide selectively induces macrolide-dependent inhibition of proliferation of the transplanted cells expressing the mutated MBP compared to endogenous cells of the animal.

5 In another embodiment, the invention provides a method for promoting engraftment and hematopoietic activity of a hematopoietic stem cell, comprising: (a) transducing the stem cells to be engrafted with a nucleic acid encoding a modified macrolide binding protein specific for a modified macrolide, e.g., to produce a transformed hematopoietic stem cell; (b) introducing the transformed hematopoietic stem cell into a recipient mammal, such that the modified cellular receptor cyclophilin is expressed; and (c) administering to the animal an effective amount of the modified cyclosporin.

10 In the subject methods described herein, such as those enumerated above, the MBP can be a FRAP, an FK506-binding protein, a cyclophilin or a calcineurin. Preferably, the mutated MBP has a dissociation constant, K_d , for a modified macrolide which is at least one order of magnitude less than the K_d of the wild-type MBP, though mutated MBP with dissociation constants at least two, three, four, five and even ten orders of magnitude less than the K_d of the wild-type MBP are contemplated.

15 The mutated MBP gene can be provided in a cell as part of an expression vector, such as a viral expression construct. In certain embodiments, the mutated MBP gene is introduced into the genome of the cell by homologous recombination or other integration techniques.

20 In preferred embodiments, the macrolide is an analog of rapamycin, FK506 or cyclosporin. Preferred cells for use in the subject methods are mammalian cells, more preferably primate cells, and even more preferably human cells.

Preferred animals for treatment by the subject methods are mammals, more preferably primates, and even more preferably humans.

25 In those instances where the engineered cells are transplanted into an animal, the cells are preferably from an autologous source.

For treatment, the subject method can be used where the treated animal is in an immunosuppressed state, e.g., as a result of radiation or chemotherapy.

30 Another aspect of the present invention provides expression constructs encoding a mutated macrolide binding protein (MBP) selected from the group consisting of FRAP, FKBP, cyclophilin and calcineurin, wherein the mutated MBP has an altered macrolide-binding specificity relative to the wild-type form MBP and, in the presence of a macrolide which binds the mutated MBP, induces macrolide-dependent inhibition of proliferation of a cell expressing the mutated MBP.

35 The present invention also provides hematopoietic cells, particularly stem cells and/or T cells, which have been engineered with such expression constructs

Yet another aspect of the present invention relates to kits for selectively inhibiting proliferation of a hematopoietic cell. The subject kits can include (i) an expression construct for ectopically expressing an MBP gene encoding a mutated macrolide binding protein (MBP) having an altered macrolide-binding specificity relative to a wild-type form of the MBP, which mutated MBP retains the ability to cause macrolide-dependent inhibition of proliferation; and (ii) a macrolide which selectively binds to the altered MBP relative to the wild-type MBP and selectively induces macrolide-dependent inhibition of proliferation of cells expressing the mutated MBP relative to cells not expressing only the wild-type MBP.

10

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a graph showing the cellular assay for calcineurin-mediated NFAT-signalling.

15 *Figure 2* is a schematic depiction of the interaction between cyclosporin A (CsA) and cyclophilin (Cph) and between a modified CsA (CsAt⁻), containing an additional methyl group, and a modified Cph (Cph^{t-}) containing mutations of F113G, S99T which create a "hole" to accommodate the methyl group of CsAt⁻.

20 *Figure 3* represents the amount of thymidine incorporated as a percent of maximal stimulation of normal peripheral lymphocytes after 48 hours incubation with anti CD3 plus CD28 and exposure to the indicated concentrations (nM) of CsA or CsAt⁻.

Figure 4 represents the percent inhibition of NF-AT dependent transcription in Jurkat cells transfected with Cph^{t-} or Cph and treated with various concentrations of CsAt⁻.

DETAILED DESCRIPTION OF THE INVENTION

25 I. General

The invention pertains to methods for regulating a biological activity of a cell, preferably in a tissue-type or cell-type specific manner. In general, the present invention provides a method for rendering a cell selectively sensitive to a macrolide analog. The present invention is based, *inter alia*, on the observation that, by compensatory mutation, 30 macrolide-dependent protein-protein interactions, e.g., mediated by macrolides, can be recapitulated in systems where the macrolide has been altered (as a "modified ligand") to no longer interact efficiently with a ligand-binding domain (LBD) of one of the proteins ("target protein") found in macrolide-dependent complexes. In particular, compensatory mutations can be made to the ligand binding domain of a target protein which is not

otherwise able to efficiently bind to the modified ligand, and in doing so render the modified target protein able to bind to the modified ligand.

According to the invention, a biological activity of a cell which is contingent on the presence or absence of macrolide-dependent protein complexes can be regulated by treatment with the modified ligand and concomitant expression of a target protein engineered to bind to the modified form of the ligand. Upon expression of the genetically engineered target protein, the modified ligand can selectively bind to or otherwise interact with the engineered protein so as to recruit and/or stabilize the formation of a macrolide-dependent protein complex. In preferred embodiments, the modified ligand will not similarly interact with or induce formation of similar complexes in wild-type cells. Thus, the invention provides the ability to selectively regulate biological events mediated by the protein target. Treatment of wild-type cells (i.e., cells which do not express the modified protein) with the modified ligand will have essentially no impact on the biological activity in those cells, whereas treatment of cells expressing the modified protein with the modified ligand will induce the biological activity.

To provide further guidance, the following three examples illustrate certain aspects of the invention:

(A) The macrolide rapamycin mediates the formation of complexes including an FK506-binding protein (FKBP), such as FKBP12 (SEQ ID NO. 1), and a FRAP (tor1) protein (SEQ ID No. 2). The formation of the rapamycin-independent complexes correlates with cell-cycle arrest in G1 phase, and is understood to be part of the mechanism by which rapamycin obtains its immunosuppressive, antiproliferative and antineoplastic activities. As described below, there are a variety of rapamycin analogs which bind FRAP and/or FKBP12 with a much reduced affinity (e.g., with K_d values which are orders of magnitude greater than rapamycin). By compensatory mutation to, for example, the ligand-binding domain of FRAP, formation of rapamycin-independent FRAP/FKBP complexes by certain of those analogs can be reestablished. Accordingly, a cell can be rendered sensitive to such rapamycin analogs by ectopic expression of a gene encoding a compensatory mutant of FRAP. Similarly, where the modification of rapamycin results in loss of efficient interaction with an FKBP, compensatory mutations to that protein can be used to provide FRAP/FKBP complexes dependent on the presence of the modified rapamycin.

(B) The macrolide FK506 can bring about certain biological events, like cell-cycle arrest, by a mechanism which apparently includes induction of FK506-

dependent complexes of an FKBP and the calcineurin protein (SEQ ID No. 3). Various analogs of FK506 can be made which disrupt the ability of the analog to interact one or both of the FKBP and calcineurin proteins, or at least disrupt the formation of macrolide-dependent complexes. As above, compensatory mutants can be provided which restore the ability of the analog to induce such biological responses as inhibition of proliferation.

5 (C) Yet another example of a macrolide-dependent system which can be usurped for use in the present invention involves the cyclosporin-dependent complexes including a cyclophilin and a calcineurin. As above, pairs of cyclosporin analogs and compensatory mutants of one or both of the cyclophilin and/or calcineurin proteins can be used to render cell populations selectively sensitive to treatment with the analog.

10 Thus, in a generic sense, the present invention provides a method for selectively inhibiting proliferation of a cell by (i) contacting the cell with a macrolide which does not 15 efficiently bind to a native macrolide binding protein (MBP) of the cell, under conditions wherein (ii) the cell ectopically expresses a mutated form of the MBP which causes inhibition of proliferation in a manner dependent on the presence of the macrolide. For example, the MBP can be engineered with compensatory mutations sufficient to decrease 20 the dissociation constant (k_d) for binding to the macrolide, e.g., relative to the native MBP, preferably by at least 1, 2, 3 or even 5 or more orders of magnitude.

In a preferred embodiment of the invention, tissue specificity for controlling the effect of treatment with the macrolide is achieved by selective transduction of a gene encoding the modified MBP, and/or by operably linking that gene to a transcriptional regulatory sequence having the desired cell-type or tissue-type specificity for expression. 25 In other embodiments, tissue specificity is provided by tissue-specific delivery of the macrolide.

30 Exemplary biological activity that can be regulated according to the method of the invention can be cellular proliferation, differentiation, and/or cell death and/or regulation of gene expression, so long as the biological activity is regulated or otherwise mediated by the ligand-crosslinked protein complex. In a preferred embodiment, the biological activity is T cell activation.

35 Exemplary target proteins which can be engineered in the practice of the subject invention include those intracellular proteins which form protein complexes in a macrolide-dependent fashion, and include cyclophilins, calcineurins, FK506 binding proteins (FKBPs) and FRAP (Tor1), which have mutated ligand binding domains for interacting with such macrolides as altered forms of cyclosporins, FK506 or rapamycin,

e.g., which effect the formation of cyclophilin-calcineurin, FKBP-calcineurin and FKBP-FRAP complexes.

II. Definitions

5 For convenience, the meaning of certain terms and phrases employed in the specification, examples, and appended claims are provided below.

10 As used herein, the term "cellular composition" refers to a preparation of cells, which preparation may include, in addition to the cells, non-cellular components such as cell culture media, e.g. proteins, amino acids, nucleic acids, nucleotides, co-enzyme, anti-15 oxidants, metals and the like. Furthermore, the cellular composition can have components which do not affect the growth or viability of the cellular component, but which are used to provide the cells in a particular format, e.g., as polymeric matrix for encapsulation or a pharmaceutical preparation.

15 The term "lineage committed cell" refers to a stem cell that is no longer pluripotent but has become restricted to a specific lineage, e.g., a myeloid, lymphoid, erythroid lineage. the lineage committed cell subsequently differentiates to specialized cell types, e.g., erythrocytes, T and B lymphocytes.

20 The term "stem cell" refers to an undifferentiated cell which is capable of self-renewal, i.e., proliferation to give rise to more stem cells, and may give rise to lineage committed progenitors which are capable of differentiation and expansion into a specific lineage. In a preferred embodiment, the term "stem cell" refers to a generalized mother cell whose descendants (progeny) specialize, often in different directions, by differentiation, e.g., by acquiring completely individual characters, as occurs in progressive diversification of embryonic cells and tissues. As used herein, the term "stem 25 cells" refers generally to both embryonic and hematopoietic stem cells from mammalian origin, e.g., human.

30 A stem cell composition is characterized by being able to be maintained in culture for extended periods of time, being capable of selection and transfer to secondary and higher order culture, and being capable of differentiating into various lymphoid or myeloid lineages, particularly B and T lymphocytes, monocytes, macrophages, neutrophils, erythrocytes and the like.

As used herein, the term "embryonic stem cell" means a pluripotent, blastocyst-derived cell that retains the developmental potential to differentiate into all somatic and

germ cell lineages (for review, *see* Robertson, E. J. (1986) *Trends in Genetics* 2: 9-13). This cell type is also referred to as an "ES cell".

As used herein, the term "hematopoietic stem cell" (HSC) means a population of cells capable of both self-renewal and differentiation into all defined hematopoietic lineages, i.e., myeloid, lymphoid or erythroid lineages; and limiting number of cells are capable of repopulating the hematopoietic system of a recipient who has undergone myeloablative treatment. HSCs can ultimately differentiate into "hematopoietic cells", including without limitation, common lymphoid progenitor cells, T cells (e.g., helper, cytotoxic, and suppressor cells), B cells, plasma cells, natural killer cells, common myeloid progenitor cells, monocytes, macrophages, mast cells, leukocytes, basophils, neutrophils, eosinophils, magakaryocytes, platelets, and erythroids. HSCs are identifiable by the presence of cell surface antigens of primitive phenotypes, e.g., CD34⁺Thy-1⁺Lin⁻, and negative staining for lineage-specific antigens.

As used herein, the term "gene" or "recombinant gene" refers to a nucleic acid molecule comprising an open reading frame and including at least one exon and (optionally) an intron sequence. The term "intron" refers to a DNA sequence present in a given gene which is not translated into protein and is generally found between exons.

As used herein, the term "nucleic acid" refers to polynucleotides such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA). The term should also be understood to include, as equivalents, derivatives, variants and analogs of either RNA or DNA made from nucleotide analogs, and, as applicable to the embodiment being described, single (sense or antisense) and double-stranded polynucleotides.

The term "operably linked" when referring to a transcriptional regulatory sequence and a coding sequence is intended to mean that the regulatory sequence is associated with the coding sequence in such a manner as to facilitate transcription of the coding sequence in an activator-dependent fashion.

As used herein, "heterologous DNA" or "heterologous nucleic acid" include DNA that does not occur naturally as part of the genome in which it is present or which is found in a location or locations in the genome that differs from that in which it occurs in nature. Heterologous DNA is not endogenous to the cell into which it is introduced, but has been obtained from another cell. Generally, although not necessarily, such DNA encodes RNA and proteins that are not normally produced by the cell in which it is expressed. Heterologous DNA may also be referred to as foreign DNA. Any DNA that one of skill in the art would recognize or consider as heterologous or foreign to the cell in which is expressed is herein encompassed by heterologous DNA.

"Transcriptional regulatory sequence", also termed herein "regulatory element", "regulatory sequence" or "regulatory element", are generic terms used throughout the specification to refer to DNA sequences, such as initiation signals, enhancers, and promoters, which induce or control transcription of protein coding sequences with which they are operably linked. The term "enhancer", also referred to herein as "enhancer element", is intended to include regulatory elements capable of increasing, stimulating, or enhancing transcription from a basic promoter. The term "silencer", also referred to herein as "silencer element" is intended to include regulatory elements capable of decreasing, inhibiting, or repressing transcription from a basic promoter. Regulatory elements can also be present in genes other than in 5' flanking sequences. Thus, it is possible that regulatory elements of a gene are located in introns, exons, coding regions, and 3' flanking sequences.

The terms "basic promoter" or "minimal promoter", as used herein, are intended to refer to the minimal transcriptional regulatory sequence that is capable of initiating transcription of a selected DNA sequence to which it is operably linked. This term is intended to represent a promoter element providing basal transcription. A basic promoter frequently consists of a TATA box or TATA-like box and is bound by an RNA polymerase and by numerous transcription factors, such as GTFs and TATA box Binding Proteins (TBPs).

The term "tissue specific regulatory element" refers to promoters and other regulatory elements which effect expression of an operably linked DNA sequence preferentially in specific cell-types or tissue-types. Gene expression occurs preferentially in a specific cell if expression in this cell type is significantly higher than expression in other cell types.

The terms "promoter" and "regulatory element" also encompass so-called "leaky" promoters and "regulatory elements", which regulate expression of a selected DNA primarily in one tissue, but cause expression in other tissues as well. The terms "promoter" and "regulatory element" also encompass non-tissue specific promoters and regulatory elements, i.e., promoters and regulatory elements which are active in most cell types. Furthermore, a promoter or regulatory element can be a constitutive promoter or regulatory element, i.e., a promoter or regulatory element which constitutively regulates transcription, as opposed to a promoter or regulatory element which is inducible, i.e., a promoter or regulatory element which is active primarily in response to a stimulus. A stimulus can be, e.g., a molecule, such as a hormone, a cytokine, a heavy metal, phorbol esters, cyclic AMP (cAMP), or retinoic acid.

As used herein, the terms "transfection" and "transduction" mean the introduction of a nucleic acid, e.g., an expression vector, into a recipient cell by nucleic acid-mediated gene transfer. The term "transduction" is generally used herein when the transfection with a nucleic acid is by viral delivery of the nucleic acid. "Transformation", as used herein, refers to a process in which a cell's genotype is changed as a result of the cellular uptake of exogenous DNA or RNA, and, for example, the transformed cell expresses a recombinant form of a polypeptide or, in the case of anti-sense expression from the transferred gene, the expression of a naturally-occurring form of the recombinant protein is disrupted.

As used herein, the term "transgene" refers to a nucleic acid sequence which has been introduced into a cell. Daughter cells deriving from a cell in which a transgene has been introduced are also said to contain the transgene (unless it has been deleted). A transgene can encode, e.g., a polypeptide, partly or entirely heterologous, i.e., foreign, to the transgenic animal or cell into which it is introduced, or, is homologous to an endogenous gene of the transgenic animal or cell into which it is introduced, but which is designed to be inserted, or is inserted, into the animal's genome in such a way as to alter the genome of the cell into which it is inserted (e.g., it is inserted at a location which differs from that of the natural gene). Alternatively, a transgene can also be present in an episome. A transgene can include one or more transcriptional regulatory sequences and any other nucleic acid, (e.g. intron), that may be necessary for optimal expression of a selected coding sequence.

By "gene product" it is meant a molecule that is produced as a result of transcription of a gene. Gene products include RNA molecules transcribed from a gene, as well as proteins translated from such transcripts.

The terms "protein", "polypeptide" and "peptide" are used interchangeably herein when referring to a gene product, e.g., as may be encoded by a coding sequence.

The terms "mutated" and "non-native" are used interchangeably herein and refer to genes and genes products which are not native (do not naturally occur) in the particular cell in which they are present, e.g., the term refers to a state relative to the cell's genotype.

Thus, mutant (or non-native) MBPs are proteins which have altered sequences relative to the host cell, and which may have been generated by, for example, mutagenesis, or which could be MBPs found naturally in other cells.

The term "interact" as used herein is meant to include detectable interactions between molecules, such as can be detected using, for example, a yeast two hybrid assay or by immunoprecipitation. The term interact is also meant to include "binding"

CONFIDENTIAL

interactions between molecules. Interactions may be, for example, protein-protein, protein-nucleic acid, protein-small molecule or small molecule-nucleic acid in nature.

The term "ligand binding domain" (or "LBD") refers to any protein, though generally a fragment thereof or derivative thereof, which binds a preselected ligand.

5 The term "wild-type ligand binding domain" refers to a ligand binding domain as it is naturally occurring in a normal cell.

The term "modified ligand binding domain" refers to any ligand binding domain which has been modified, or altered to decrease binding of the naturally occurring ligand to the modified LBD. The modified LBD is preferably capable of interacting specifically 10 with a modified ligand, which is not capable of interacting significantly with the naturally occurring ligand binding domain. A modification of a ligand may consist of the addition, deletion or substitution of at least one atom or chemical moiety of the ligand. If the ligand is a proteinous compound, the modification can be an addition, deletion, or substitution of one or more amino acids or the modification of at least one amino acid.

15 The term "ligand" refers to any molecule which is capable of interacting with a receptor. A ligand can be naturally occurring, or the ligand can be partially or wholly synthetic. Preferred ligands include macrolides, e.g., cyclosporin A, FK506, and rapamycin and analogs thereof.

20 The term "modified ligand" refers to a ligand which has been modified such that it does not significantly interact with the naturally occurring receptor of the ligand in its non modified form.

25 As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of preferred vector is an episome, i.e., a nucleic acid capable of extra-chromosomal replication. Preferred vectors are those capable of autonomous replication and/or expression of nucleic acids to which they are linked. Vectors capable of directing the expression of genes to which they are operatively linked are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of 30 "plasmids" which refer generally to circular double stranded DNA loops which, in their vector form are not bound to the chromosome. In the present specification, "plasmid" and "vector" are used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors which serve equivalent functions and which become known in the art subsequently hereto.

“Derived from” as that phrase is used herein indicates a peptide or nucleotide sequence selected from within a given sequence. A peptide or nucleotide sequence derived from a named sequence may contain a small number of modifications relative to the parent sequence, in most cases representing deletion, replacement or insertion of less than about 5 15%, preferably less than about 10%, and in many cases less than about 5%, of amino acid residues or base pairs present in the parent sequence. In the case of DNAs, one DNA molecule is also considered to be derived from another if the two are capable of selectively hybridizing to one another.

10 As used herein, the term “animal” refers to mammals, preferably mammals such as humans. Likewise, a “patient” or “subject” to be treated by the method of the invention can mean either a human or non-human animal.

15 A “disease of a hematopoietic cell” refers to any condition characterized by impairment of any normal function of a hematopoietic cell. The diseases of hematopoietic cells that can be treated utilizing the cells of the present invention include, without limitation, genetic disorders (e.g., Adenosine Deaminase Deficiency, Fanconis’ Anemia, and hemoglobinopathies such as Sickle Cell Anemia, Thalassemias, and Hemoglobin C Disease), as well as diseases acquired by infectious or non-infectious means (e.g., Acquired Immune Deficiency Syndrome and leukemias).

20 A “discordant species combination”, as used herein, refers to two species in which hyperacute rejection occurs when vascular organs are grafted. Generally, discordant species are from different orders, while non-discordant species are from the same order.

III. Exemplary Modified Macrolides and Macrolide-binding proteins

25 The modified target proteins are those forms of a protein which, relative to a naturally occurring form of the protein, have been altered at the amino acid level to increase the binding affinity of the target protein or a complex including the target protein for a modified macrolide ligand. Generally, such alterations will be made to a ligand binding domain of the target protein.

30 A wide range of techniques are known in the art for generating the modified target proteins of the present invention. In one embodiment, crystallographic or other structural data pertaining to the interaction of the normal ligand with the native protein can be consulted to predict compensatory mutations to the protein to restore binding to the modified ligand. In other embodiments, combinatorial mutagenesis can be used to isolate mutated forms of the target protein by their binding affinity for the modified ligand. The

mutations introduced into the target protein can involve changes in amino acid residues known to be at the binding site, or by random or semi-random mutagenesis.

There are a host of methods available in the art for screening gene products of variegated gene libraries made by combinatorial mutagenesis, especially for identifying individual gene products having a certain binding property. Such techniques will be generally adaptable for rapid screening of gene libraries generated by the combinatorial mutagenesis of, for example, the macrolide binding domain of any of an FKBP, cyclophilin, calcineurin and/or FRAP protein. The most widely used techniques for screening large gene libraries typically comprises cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates relatively easy isolation of the vector encoding the gene whose product was detected. Each of the illustrative assays described below are amenable to high through-put analysis as necessary to screen large numbers of degenerate ligand binding domain sequences created by combinatorial mutagenesis techniques.

In one screening assay, the candidate ligand binding domains are displayed on the surface of a cell or viral particle, preferably in truncated form, and the ability of particular cells or viral particles to bind as appropriate, e.g., FK506, cyclosporin or rapamycin (or a protein complex thereof) via the displayed ligand binding domain is detected in a "panning assay". For instance, the degenerate LBD gene library can be cloned into the gene for a surface membrane protein of a bacterial cell, and the resulting fusion protein detected by panning protocols (see, for example, Ladner *et al.*, WO 88/06630; Fuchs *et al.* (1991) *Bio/Technology* 9:1370-1371; and Goward *et al.* (1992) *TIBS* 18:136-140). In a similar fashion, fluorescently labeled molecules which bind the LBD, such as fluorescently labeled forms of the altered macrolide alone or in preformed protein complexes, can be used to score for ligand binding domains which are capable of interacting with the modified ligand. Cells can be visually inspected and separated under a fluorescence microscope, or, where the morphology of the cell permits, separated by a fluorescence-activated cell sorter.

In an alternate embodiment, the gene library is expressed as a fusion protein on the surface of a viral particle. For instance, in the filamentous phage system, foreign peptide sequences can be expressed on the surface of infectious phage, thereby conferring two significant benefits. First, since these phage can be applied to affinity matrices at very high concentrations, a large number of phage can be screened at one time. Second, since each infectious phage displays the combinatorial gene product on its surface, if a particular phage is recovered from an affinity matrix in low yield, the phage can be amplified by another round of infection. The group of almost identical *E.coli* filamentous phages M13,

fd, and f1 are most often used in phage display libraries, as either of the phage gIII or gVIII coat proteins can be used to generate fusion proteins without disrupting the ultimate packaging of the viral particle (Ladner *et al.* PCT publication WO 90/02909; Garrard *et al.*, PCT publication WO 92/09690; Marks *et al.* (1992) *J. Biol. Chem.* 267:16007-16010; 5 Griffiths *et al.* (1993) *EMBO J.* 12:725-734; Clackson *et al.* (1991) *Nature* 352:624-628; and Barbas *et al.* (1992) *PNAS* 89:4457-4461).

In an illustrative embodiment, the recombinant phage antibody system (RPAS, Pharmacia Catalog number 27-9400-01) can be easily modified for use in expressing and screening LBD combinatorial libraries. For instance, the pCANTAB 5 phagemid of the 10 RPAS kit contains the gene which encodes the phage gIII coat protein. A combinatorial library of coding sequences for macrolide binding domains can be cloned into the phagemid adjacent to the gIII signal sequence such that it will be expressed as a gIII fusion protein. After ligation, the phagemid is used to transform competent *E. coli* TG1 cells. Transformed cells are subsequently infected with M13KO7 helper phage to rescue the 15 phagemid and its candidate LBD gene insert. The resulting recombinant phage contain phagemid DNA encoding a specific candidate protein, and display one or more copies of the corresponding fusion coat protein. The phage-displayed candidate LBD which are capable of binding to the modified macrolide, or a complex thereof, are selected or enriched by panning. For instance, a phage library of mutant LBDs derived from FKBP12 20 can be panned on a polymer-immobilized form of the modified FK506, and unbound phage washed away from the insoluble matrix. The bound phage is then isolated, and if the recombinant phage express at least one copy of the wild type gIII coat protein, they will retain their ability to infect *E. coli*. Thus, successive rounds of reinfection of *E. coli*, and panning will greatly enrich for variant LBDs retaining the ability to bind to the 25 modified FK506 in each round.

In light of the present disclosure, a variety of forms of mutagenesis generally applicable will be apparent to those skilled in the art, and most will be amenable to the aforementioned combinatorial mutagenesis approach. For example, modified ligand binding domains which can bind to the modified ligand can be generated and screened 30 using, for example, alanine scanning mutagenesis and the like (Ruf *et al.* (1994) *Biochemistry* 33:1565-1572; Wang *et al.* (1994) *J Biol Chem* 269:3095-3099; Balint *et al.* (1993) *Gene* 137:109-118; Grodberg *et al.* (1993) *Eur J Biochem* 218:597-601; Nagashima *et al.* (1993) *J Biol Chem* 268:2888-2892; Lowman *et al.* (1991) *Biochemistry* 30:10832-35 10838; and Cunningham *et al.* (1989) *Science* 244:1081-1085), by linker scanning mutagenesis (Gustin *et al.* (1993) *Virology* 193:653-660; Brown *et al.* (1992) *Mol Cell Biol* 12:2644-2652; McKnight *et al.* (1982) *Science* 232:316); or by saturation mutagenesis (Meyers *et al.* (1986) *Science* 232:613).

Where mutagenesis of a fragment of the full length target protein is carried out, the coding sequence for an isolated modified form of that fragment is reengineered back into the context of the full length gene, or a portion sufficient to induce the desired biological activity, such as by techniques used to generate fusion proteins.

5 In preferred embodiments, the modified ligand binding domain binds to the modified ligand with a dissociation constant approaching that observed for interaction of the wild-type macrolide receptor and unmodified ligand. In preferred embodiments, the target protein is modified to contain ligand-binding domains which bind to a preselected modified macrolide with a K_d value below about $10^6 M$, more preferably below about 10^7

10 M , even more preferably below about $10^8 M$, and in some embodiments below about $10^9 M$. Other modified macrolide binding domains useful in the present invention, including mutants thereof, are described in the art. See, for example, WO96/41865, WO96/13613, WO96/06111, WO96/06110, WO96/06097, WO96/12796, WO95/05389, WO95/02684, WO94/18317, each of which is expressly incorporated by reference herein.

15 In selecting a modified ligand, e.g., a modified macrolide, for use in the subject method, there are a number of readily observable or measurable criteria which can be (optionally) considered: (A) the ligand is physiologically acceptable (i.e., lacks undue toxicity towards the cell or animal for which it is to be used), (B) it has a reasonable therapeutic dosage range, (C) desirably (for applications in whole animals), it can be taken 20 orally (is stable in the gastrointestinal system and absorbed into the vascular system), (D) it can cross the cellular and other membranes, as necessary, and (E) binds to a modified ligand binding domain with reasonable affinity for the desired application. A first desirable criterion is that the compound is relatively physiologically inert, but for its activating capability with the modified protein complexes. The less the ligand binds to 25 native macrolide binding proteins, and the lower the proportion of total ligand which binds to such proteins, the better the response will normally be. Particularly, the ligand should not have a strong biological effect on native proteins.

Preferred ligands include modified forms of cyclosporin A, FK506, FK520, or rapamycin.

30 Illustrative of this situation, one can modify the groups at position 9 or 10 of FK506 or FK520 (see Van Duyne *et al* (1991) *Science* 252, 839), so as to increase their steric requirement, by replacing the hydroxyl with a group having greater steric requirements, or by modifying the carbonyl at position 10, replacing the carbonyl with a group having greater steric requirements or functionalizing the carbonyl, *e.g.* forming an 35 N-substituted Schiff's base or imine, to enhance the bulk at that position. Various functionalities which can be conveniently introduced at those sites are alkyl groups to form

ethers, acylamido groups, N-alkylated amines, where a 2-hydroxyethylimine can also form a 1,3-oxazoline, or the like. Generally, the substituents will be from about 1 to 6, usually 1 to 4, and more usually 1 to 3 carbon atoms, with from 1 to 3, usually 1 to 2 heteroatoms, which will usually be oxygen, sulfur, nitrogen, or the like. By using different derivatives of the basic structure, one can create different ligands with different conformational requirements for binding. By mutagenizing FK506 ligand binding domains, such as from FKBP12, one can have create a library of potential binding domains which will have different affinities for these modified forms of FK506 or FK520.

For instances, Substituents at C9 and C10 of FK506, which can be and have been accessed by synthesis, clash with a distinct set of FKBP12 sidechain residues. Thus, one class of mutant receptors for such ligands should contain distinct modifications, one creating a compensatory hole for the C10 substituent and one for the C9 substituent. As described in U.S. Patent Application Serial No. 08/388,653 by Crabtree et al., carbon 10 was selectively modified to have either an N-acetyl or N-formyl group projecting from the carbon (vs. a hydroxyl group in FK506). The binding properties of these derivatives clearly reveal that these C10 bumps effectively abrogate binding to the native FKBP12. U.S. Patent Application Serial No. 08/388,653 by Crabtree et al. depicts schemes for the synthesis of FK506-type moieties containing additional C9 bumps.

This invention thus encompasses use of a class of FK-506-type compounds comprising an FK-506-type moiety which contains, at one or both of C9 and C10, a functional group comprising -OR, -R, -(CO)OR, -NH(CO)H or -NH(CO)R, where R is substituted or unsubstituted, alkyl or arylalkyl which may be straightchain, branched or cyclic, including substituted or unsubstituted peroxides, and carbonates. "FK506-type moieties" include FK506, FK520 and synthetic or naturally occurring variants, analogs and derivatives thereof (including rapamycin) which retain at least the (substituted or unsubstituted) C2 through C15 portion of the ring structure of FK-506 and are capable of binding with a natural or modified FKBP, preferably with a K_d value below about $10^{-6} M$.

Another preferred modified ligand includes FK506 molecules having an electrophilic addition "bump" at the C9 position of FK506, generating 9-S-methoxy-FK506 that does not bind endogenous FKBP, but does bind to FKBP12F36V.

To accomodate a substituent at positions 9 or 10 of FK506 or FK520, one can modify FKBP12's Phe36 to Ala and/or Asp37 to Gly or Ala. In particular, mutant FKBP12 moieties which contain Val, Ala, Gly, Met or other small amino acids in place of one or more of Tyr26, Phe36, Asp37, Tyr82 and Phe99 are of particular interest as receptor domains for FK506-type and FK-520-type ligands containing modifications at C9 and/or C10.

Site-directed mutagenesis may be conducted using the megaprimer mutagenesis protocol (see e.g., Sakar and Sommer, *BioTechniques* 8 4 (1990): 404-407). cDNA sequencing is performed with the Sequenase kit. Expression of mutant FKBP12s may be carried out in the plasmid pHN1⁺ in the *E. coli* strain XA90 since many FKBP12 mutants have been expressed in this system efficiently. Mutant proteins may be conveniently purified by fractionation over DE52 anion exchange resin followed by size exclusion on Sepharose as described elsewhere. See e.g. Aldape et al, *J Biol Chem* 267 23 (1992): 16029-32 and Park et al, *J Biol Chem* 267 5 (1992): 3316-3324. Binding constants may be readily determined by one of two methods. If the mutant FKBP_s maintain sufficient rotamase activity, the standard rotamase assay may be utilized. See e.g., Galat et al, *Biochemistry* 31 (1992): 2427-2434. Otherwise, the mutant FKBP12s may be subjected to a binding assay using LH20 resin and radiolabeled T2-dihydroFK506 and T2-dihydroCsA that we have used previously with FKBP_s and cyclophilins. Bierer et al, *Proc. Natl. Acad. Sci. U.S.A.* 87 4 (1993): 555-69.

The invention further provides modified cyclosporin A that cannot bind to its cellular receptor cyclophilin (CypA). As described in the Examples, this rationally modified cyclosporin A is called *alpha*-cyclopentyl, sarcosine11-CsA (CpSar11-CsA). In addition, the inventors designed and synthesized a cellular receptor cyclophilin (Cyp) with compensatory mutations in its cyclosporin A binding pocket that can form tight complexes with CpSar11-CsA. The rationally designed CpSar11-CsA and its genetically engineered Cyp receptor provide a method to inhibit calcineurin conditionally and tissue specifically through selective expression of this modified cyclophilin receptor.

In another embodiment, modified CsA derivatives for use in the subject invention are CsA analogs in which (a) NMeVal11 is replaced with NMePhe (which may be substituted or unsubstituted) or NMeThr (which may be unsubstituted or substituted on the threonine betahydroxyl group) or (b) the *pro-S* methyl group of NMeVal11 is replaced with a bulky group of at least 2 carbon atoms, preferably three or more, which may be straight, branched and/or contain a cyclic moiety, and may be alkyl (ethyl, or preferably propyl, butyl, including t-butyl, and so forth), aryl, or arylalkyl. These compounds include those CsA analogs which contain NMeLeu, NMeIle, NMePhe or specifically the unnatural NMe[*beta*MePhe], in place of MeVal11. The "(b)" CsA compounds are of formula 2 where R represents a functional group as discussed above.

A two step strategy may be used to prepare the modified [MeVal¹¹]CsA derivatives starting from CsA. In the first step the residue MeVal11 is removed from the macrocycle. In the second step a selected amino acid is introduced at the (former) MeVal11 site and the linear peptide is cyclized. The synthesis of this compound is further described, e.g., in U.S. Applications Serial No. 08/388,653. Mutant cyclophilins that bind such CsA variants

by accomodating the extra bulk on the ligand can be prepared and identified, e.g., through the structure-based site-directed and random mutagenesis/screening protocols, e.g., as described in the FK1012 studies.

Similar considerations apply to the generation of mutant FRAP-derived domains which bind preferentially to rapamycin analogs (rapalogs) containing modifications (i.e., are 'bumped') relative to rapamycin in the FRAP-binding effector domain. For example, one may obtain preferential binding using rapalogs bearing substituents other than -OMe at the C7 position with FRBs based on the human FRAP FRB peptide sequence but bearing amino acid substitutions for one or more of the residues Tyr2038, Phe2039, 5 Thr2098, Gln2099, Trp2101 and Asp2102. Exemplary mutations include Y2038H, Y2038L, Y2038V, Y2038A, F2039H, F2039L, F2039A, F2039V, D2102A, T2098A, 10 T2098N, and T2098S. Rapalogs bearing substituents other than -OH at C28 and/or substituents other than =O at C30 may be used to obtain preferential binding to FRAP 15 proteins bearing an amino acid substitution for Glu2032. Exemplary mutations include E2032A and E2032S. Proteins comprising an FRB containing one or more amino acid replacements at the foregoing positions, libraries of proteins or peptides randomized at those positions (i.e., containing various substituted amino acids at those residues), libraries randomizing the entire protein domain, or combinations of these sets of mutants are made 20 using the procedures described above to identify mutant FRAPs that bind preferentially to bumped rapalogs.

Further guidance for identifying compensatory mutations to macrolide-binding domains are provided below:

Selection of Compensatory Mutations in FKBP12 for Bump-FK506s Using the Yeast Two-Hybrid System

One approach to obtaining variants of receptor proteins or domains, including of FKBP12, is the powerful yeast "two-hybrid" or "interaction trap" system. The two-hybrid system has been used to detect proteins that interact with each other. A "bait" fusion protein consisting of a target protein fused to a transcriptional activation domain is co-expressed with a cDNA library of potential "hooks" fused to a DNA-binding domain. A protein-protein (bait-hook) interaction is detected by the appearance of a reporter gene product whose synthesis requires the joining of the DNA-binding and activation domains. The yeast two-hybrid system mentioned here was originally developed by Elledge and co-workers. Durfee et al, *Genes & Development* 7 4 (1993): 555-69 and Harper et al, *Cell* 75 30 35 4 (1993): 805-816.

Since the two-hybrid system per se cannot provide insights into receptor-ligand interactions involving small molecule, organic ligands, we have developed a new, FK1012-inducible transcriptional activation system (discussed below). Using that system one may extend the two hybrid system so that small molecules (e.g., FK506s or FK1012s 5 or FK506-type molecules of this invention) can be investigated. One first generates a cDNA library of mutant FKBP (the hooks) with mutations that are regionally localized to sites that surround C9 and C10 of FK506. For the bait, two different strategies may be pursued. The first uses the ability of FK506 to bind to FKBP12 and create a composite 10 surface that binds to calcineurin. The sequence-specific transcriptional activator is thus comprised of: DNA-binding domain-mutant FKBP12---bump-FK506---calcineurin A-activation domain (where --- refers to a noncovalent binding interaction). The second strategy uses the ability of FK1012s to bind two FKBP simultaneously. A HED version 15 of an FK1012 may be used to screen for the following ensemble: DNA-binding domain-mutant FKBP12---bump-FK506---normal FK506---wildtype FKBP12-activation domain.

15

1. *Calcineurin-Gal4 activation domain fusion as a bait:* A derivative of pSE1107 that contains the Gal4 activation domain and calcineurin A subunit fusion construct has been constructed. Its ability to act as a bait in the proposed manner has been verified by studies using the two-hybrid system to map out calcineurin's FKBP-FK506 binding site.

20

2. *hFKBP12-Gal4 activation domain fusion as a bait:* hFKBP12 cDNA may be excised as an EcoRI-HindIII fragment that covers the entire open reading frame, blunt-ended and ligated to the blunt-ended Xho I site of pSE1107 to generate the full-length hFKBP-Gal4 activation domain protein fusion.

25

3. *Mutant hFKBP12 cDNA libraries* hFKBP12 may be digested with EcoRI and HindIII, blunted and cloned into pAS1 (Durfee et al, *supra*) that has been cut with NcoI and blunted. This plasmid is further digested with NdeI to eliminate the NdeI fragment 30 between the NdeI site in the polylinker sequence of pAS1 and the 5' end of hFKBP12 and religated. This generated the hFKBP12-Gal4 DNA binding domain protein fusion. hFKBP was reamplified. Mutant hFKBP12 cDNA fragments were then prepared using the primers listed below that contain randomized mutant sequences of hFKBP at defined positions by the polymerase chain reaction, and were inserted into the Gal4 DNA binding domain-hFKBP(NdeI/BamHI) construct.

35

4. *Yeast strain* *S. cerevisiae* Y153 carries two selectable marker genes (*his3*/ -galactosidase) that are integrated into the genome and are driven by Gal4 promoters. (Durfee, *supra*.)

5 *Using Calcineurin-Gal4 Activation Domain as Bait*

The FKBP12-FK506 complex binds with high affinity to calcineurin, a type 2B protein phosphatase. Since we use C9- or C10-bumped ligands to serve as a bridge in the two-hybrid system, only those FKBP from the cDNA library that contain a compensatory mutation generate a transcriptional activator. For convenience, one may prepare at least 10 three distinct libraries (using primers 11207-11209, Primer Table) that will each contain 8,000 mutant FKBP12s. Randomized sites were chosen by inspecting the FKBP12-FK506 structure, which suggested clusters of residues whose mutation might allow binding of the offending C9 or C10 substituents on bumped FK506s. The libraries are then individually screened using both C9- and C10-bumped FK506s. The interaction between a bumped-FK506 and a compensatory hFKBP12 mutant can be detected by the ability of host yeast 15 to grow on *his* drop-out medium and by the expression of -galactosidase gene. Since this selection is dependent on the presence of the bumped-FK506, false positives can be eliminated by subtractive screening with replica plates that are supplemented with or without the bumped-FK506 ligands.

20

Using hFKBP12-Gal4 Activation Domain as Bait

Using the calcineurin A-Gal4 activation domain to screen hFKBP12 mutant cDNA libraries is a simple way to identify compensatory mutations on FKBP12. However, 25 mutations that allow bumped-FK506s to bind hFKBP12 may disrupt the interaction between the mutant FKBP12---bumped-FK506 complex and calcineurin. If the initial screening with calcineurin as a bait fails, the wildtype hFKBP12-Gal4 activation domain will instead be used. An FK1012 HED reagent consisting of: native-FK506-bumped-FK506 (Figure 16) may be synthesized and used as a hook. The FK506 moiety of the FK1012 can bind the FKBP12-Gal4 activation domain. An interaction between the 30 bumped-FK506 moiety of the FK1012 and a compensatory mutant of FKBP12 will allow host yeast to grow on *his* drop-out medium and to express -galactosidase. In this way, the selection is based solely on the ability of hFKBP12 mutant to interact with the bumped-FK506. The same subtractive screening strategy can be used to eliminate false positives.

In addition to the in vitro binding assays discussed earlier, an in vivo assay may be used to determine the binding affinity of the bumped-FK506s to the compensatory hFKBP12 mutants. In the yeast two-hybrid system, -gal activity is determined by the degree of interaction between the "bait" and the "prey". Thus, the affinity between the 5 bumped-FK506 and the compensatory FKBP12 mutants can be estimated by the corresponding -galactosidase activities produced by host yeasts at different HED (native-FK506–bumped-FK506) concentrations.

Using the same strategy, additional randomized mutant FKBP12 cDNA libraries may be created in other bump-contact residues with low-affinity compensatory FKBP12 10 mutants as templates and may be screened similarly.

Phage Display Screening for High-Affinity Compensatory FKBP Mutations

Some high-affinity hFKBP12 mutants for bump-FK506 may contain several combined point mutations at discrete regions of the protein. The size of the library that 15 contains appropriate combined mutations can be too large for the yeast two-hybrid system's capacity (e.g., $>10^8$ mutations). The use of bacteriophage as a vehicle for exposing whole functional proteins should greatly enhance the capability for screening a large numbers of mutations. See e.g. Bass et al, Proteins: Structure, Function & Genetics 8 4 (1990): 309-14; McCafferty et al, Nature 348 6301 (1990): 552-4; and Hoogenboom, 20 Nucl Acids Res 19 15 (1991): 4133-7. If the desired high-affinity compensatory mutants is not be identified with the yeast two-hybrid system, a large number of combined mutations can be created on hFKBP12 with a phage vector as a carrier. The mutant hFKBP12 fusion 25 phages can be screened with bumped-FK506-Sepharose as an affinity matrix, which can be synthesized in analogy to our original FK506-based affinity matrices. Fretz et al, J Am Chem Soc 113 4 (1991): 1409-1411. Repeated rounds of binding and phage amplification should lead to the identification of high-affinity compensatory mutants.

Illustrative publications providing additional information concerning synthetic techniques and modifications relevant to FK506 and related compounds include: GB 2 244 991 A; EP 0 455 427 A1; WO 91/17754; EP 0 465 426 A1, US 5,023,263, WO 92/00278, 30 and PCT/US93/01617.

IV. Nucleic Acids Encoding Modified Macrolide-binding proteins

The invention provides nucleic acids encoding the modified macrolide-binding proteins. In general, nucleic acids encoding wild-type forms of the receptors can be 35 obtained according to methods known in the art. For example, a nucleic acid encoding a

receptor can be obtained, e.g., by reverse transcription polymerase chain reaction (RT-PCR) amplification of RNA or PCR amplification of DNA using primers hybridizing to the ends of the nucleic acid desired to be amplified according to methods well known in the art. The nucleotide sequence of the nucleic acids encoding receptors can be found in the litterature or in GenBank, which is publicly accessible on the internet. The template RNA for use in the RT-PCR can be obtained from any cell expressing the transcription factor or DNA binding domain or ligand binding domain. Template DNA can be obtained from any cell, even cells which do not express the desired factor. However, when using DNA as a template, it is preferable to avoid including introns in the construct.

The DNA can be amplified from template RNA or DNA from any species including vertebrates, such as mammals. For gene therapy, the receptor is preferably isolated from a species corresponding to the species of the recipient of the receptor. For example, for gene therapy in humans, the receptor is preferably of human origin. RNA and DNA can be extracted from cells according to methods known in the art.

Further manipulation of the wild-type sequence, e.g., to produce the compensatory mutants, can be carried out by standard molecular biology techniques.

In a preferred embodiment, a DNA encoding the modified target protein is operably linked to a promoter or regulatory element having the desired tissue specificity. Various tissue specific promoters and regulatory elements are known in the art and their nucleic acid sequences are publicly available in GenBank, freely accessible on the internet. Examples of tissue-specific promoters which can be used include the albumin promoter (liver-specific; Pinkert et al. (1987) Genes Dev. 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) Adv. Immunol. 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) EMBO J. 8:729-733) and immunoglobulins (Banerji et al. (1983) Cell 33:729-740; Queen and Baltimore (1983) Cell 33:741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle (1989) Proc. Natl. Acad. Sci. U.S.A. 86:5473-5477), pancreas-specific promoters (Edlund et al. (1985) Science 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. <=6> 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the murine box promoters Kessel and Gruss (1990) Science 249:374-379) and the alpha -fetoprotein promoter (Campes and Tilghman (1989) Genes Dev. 3:537-546). Particularly preferred promoters include T cell specific promoters, such as promoters of T cell receptor genes, CD4 promoter (GenBank Accession No. U01066), and MHC class II promoters (e.g., GenBank Accession No. M81180).

Other regulatory elements of interest for practicing the invention include inducible promoters, which can also be tissue specific. For example, certain regulatory elements are responsive to hormones, such as steroid hormones (e.g., glucocorticoid hormone, MMTV promoter), metal ions (e.g., metallothionein promoter), phorbol esters (TRE elements), or 5 calcium ionophores. Yet other inducible promoters include the growth hormone promoter; promoters which would be inducible by the helper virus such as adenovirus early gene promoter inducible by adenovirus E1A protein, or the adenovirus major late promoter; herpesvirus promoter inducible by herpesvirus proteins such as VP16 or 1CP4; promoters inducible by a vaccinia or pox virus RNA polymerases; or bacteriophage promoters such 10 as T7, T3 and SP6, which are inducible by T7, T3, or SP6 RNA polymerases, respectively.

Other systems permitting an inducible expression of the target protein include tetracyclin-responsive promoters include. Tight control of gene expression in eucaryotic cells has been achieved by use of tetracycline-responsive promoters. Such systems include the "off-switch" systems, in which the presence of tetracyclin inhibits expression, or the 15 "reversible" Tet system, in which a mutant of the *E. coli* TetR is used, such that the presence of tetracyclin induces expression. These systems are disclosed, e.g., in Gossen and Bujard (*Proc. Natl. Acad. Sci. U.S.A.* (1992) 89:5547) and in U.S. Patents 5,464,758; 5,650,298; and 5,589,362 by Bujard et al. Accordingly, a gene encoding a target protein 20 of the invention can be operably linked to an element responsive to the tetracyclin receptor or mutant form thereof, such that expression of a target gene of the invention is either induced or repressed in the presence of tetracyclin, depending on the system used.

In other embodiments, constitutive promoters may be desirable. There are many strong constitutive promoters that will be suitable for use in the invention, including the adenovirus major later promoter, the cytomegalovirus immediate early promoter, the beta 25 actin promoter, or the beta globin promoter. Many others are known in the art.

For expression of a modified target protein in a cell, a nucleic acid encoding the modified target protein which is operably linked to a promoter is preferably inserted into a vector or plasmid, generally referred to herein as "construct". The constructs can be prepared in conventional ways, where the genes and regulatory regions may be isolated, as 30 appropriate, ligated, cloned in an appropriate cloning host, analyzed by restriction or sequencing, or other convenient means. Particularly, using PCR, individual fragments including all or portions of a functional unit may be isolated, where one or more mutations may be introduced using "primer repair", ligation, *in vitro* mutagensis, *etc.* as appropriate. The construct(s) once completed and demonstrated to have the appropriate sequences may 35 then be introduced into the host cell by any convenient means. The constructs may be integrated and packaged into non-replicating, defective viral genomes like Adenovirus, Adeno-associated virus (AAV), or Herpes simplex virus (HSV) or others, including

retroviral vectors, for infection or transduction into cells. The constructs may include viral sequences for transfection, if desired. Alternatively, the construct may be introduced by fusion, electroporation, biolistics, transfection, lipofection, or the like. The host cells will usually be grown and expanded in culture before introduction of the construct(s), followed by the appropriate treatment for introduction of the construct(s) and integration of the construct(s). The cells will then be expanded and screened by virtue of a marker present in the construct. Various markers which may be used successfully include *hprt*, neomycin resistance, thymidine kinase, hygromycin resistance, etc.

In some instances, one may have a target site for homologous recombination, where it is desired that a an expression construct for the modified target protein be integrated at a particular locus. For example, it can knock-out an endogenous gene for the target protein and replace it (at the same locus or elsewhere) with the gene encoded for by the construct using materials and methods as are known in the art for homologous recombination. Alternatively, instead of providing a gene encoding a modified target protein, one may modify the endogenous gene encoding the wild-type target protein by, e.g., homologous recombination, such that it encodes the modified form of the protein. See, for example, Thomas and Capecchi, *Cell* (1987) 51, 503-512; Mansour, *et al.*, *Nature* (1988) 336, 348-352; and Joyner, *et al.*, *Nature* (1989) 338, 153-156.

Vectors containing useful elements such as bacterial or yeast origins of replication, selectable and/or amplifiable markers, promoter/enhancer elements for expression in procaryotes or eucaryotes, etc. which may be used to prepare stocks of construct DNAs and for carrying out transfections are well known in the art, and many are commercially available.

The expression constructs of the present invention may be provided in any biologically effective carrier, e.g. any formulation or composition capable of effectively transfecting cells *ex vivo* or *in vivo* with the expression construct. Efficient DNA transfer methods have been developed for hematopoietic cells (see, for example, Keating et al. 5 (1990) *Exp Hematol* 18:99-102; and Dick et al. (1986) *Trends Genet* 2:165; and U.S. patents 5,654,185, 5,498,537 and 5,399,346). Approaches include insertion of the subject gene in viral vectors including recombinant retroviruses, adenovirus, adeno-associated virus, and herpes simplex virus-1, or eukaryotic plasmids. Viral vectors can be used to transfect cells directly; plasmid DNA can be delivered with the help of, for example, 10 cationic liposomes (lipofectin) or derivatized (e.g. antibody conjugated), polylysine conjugates, gramicidin S, artificial viral envelopes or other such intracellular carriers, as well as direct injection of the gene construct or CaPO₄ precipitation carried out. It will be appreciated that because transduction of appropriate target cells represents the critical first 15 step in gene therapy, choice of the particular gene delivery system will depend on such factors as the phenotype, e.g., the degree of commitment the stem cell has undergone, if any. Another factor in the selection of the appropriate transfection formulation is the consideration raised by *ex vivo* transfection versus *in vivo* transfection, with the latter requiring consideration of the route of administration, e.g. locally or systemically.

A preferred approach for both *ex vivo* or *in vivo* introduction of the subject target 20 protein gene construct into a cell is by use of a viral vector containing the target protein gene. Infection of cells with a viral vector has the advantage that a large proportion of the targeted cells can receive the nucleic acid. Additionally, molecules encoded within the viral vector, e.g., by a cDNA contained in the viral vector, are expressed efficiently in cells which have taken up viral vector nucleic acid.

25 Retrovirus vectors are generally understood to be one of the recombinant gene delivery system of choice for the transfer of exogenous genes into stem cells, particularly into humans cells. (see e.g., Hawley R. G., *et al* (1994) *Gene Therapy* 1: 136-38)). These vectors provide efficient delivery of genes into cells, and the transferred nucleic acids are stably integrated into the chromosomal DNA of the host. A major prerequisite for the use 30 of retroviruses is to ensure the safety of their use, particularly with regard to the possibility of the spread of wild-type virus in the cell population. The development of specialized cell lines (termed "packaging cells") which produce only replication-defective retroviruses has increased the utility of retroviruses as a gene delivery system, and defective retroviruses are well characterized for use in gene transfer for gene therapy purposes (for a review, see 35 Miller, A.D. (1990) *Blood* 76:271). Thus, recombinant retrovirus can be constructed in which part of the retroviral coding sequence (*gag*, *pol*, *env*) has been replaced by the target

protein gene, rendering the retrovirus replication defective. The replication defective retrovirus is then packaged into virions which can be used to infect a target cell through the use of a helper virus by standard techniques. Protocols for producing recombinant retroviruses and for infecting cells *ex vivo* or *in vivo* with such viruses can be found in 5 Ausubel et al., *supra*, Sections 9.10-9.14 and other standard laboratory manuals. Examples of suitable retroviruses include pLJ, pZIP, pWE and pEM which are well known to those skilled in the art. Examples of suitable packaging virus lines for preparing both ecotropic and amphotropic retroviral systems include YCrip, YCre, Y2 and YAm.

10 Retroviruses have been used to introduce a variety of genes into many different cell types, including embryonic stem cells, bone marrow cells, lymphocytes, hepatocytes, and neuronal cells by both *ex vivo* and *in vivo* protocols (see for example Eglitis, et al. (1985) *Science* 230:1395-1398; Danos and Mulligan (1988) *Proc. Natl. Acad. Sci. USA* 85:6460-6464; Wilson et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:3014-3018; Armentano et al. (1990) *Proc. Natl. Acad. Sci. USA* 87:6141-6145; Huber et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:8039-8043; Ferry et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:8377-15 8381; Chowdhury et al. (1991) *Science* 254:1802-1805; van Beusechem et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:7640-7644; Kay et al. (1992) *Human Gene Therapy* 3:641-647; Dai et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:10892-10895; Hwu et al. (1993) *J. Immunol.* 150:4104-4115; U.S. Patent No. 4,868,116; U.S. Patent No. 4,980,286; PCT 20 Application WO 89/07136; PCT Application WO 89/02468; PCT Application WO 89/05345; and PCT Application WO 92/07573).

25 Exemplary retroviral vectors have been described that yield a high titre virus capable of efficiently transducing and expressing genes in undifferentiated embryonic and hematopoietic cells (Hawley et al (1994) *Gene Therapy* 1: 136-38). These vectors contain a selectable marker (*neo*, *hph* or *pac*) under the transcriptional control of an internal murine *pgk* promoter and unique restriction sites for insertion of genes downstream of a variant LTR from the retroviral mutant PCMV (PCC4 embryonal carcinoma cell-passaged myeloproliferative sarcoma virus). A variant of the above-described retroviral vectors, the Murine Stem Cell Virus (MSCV), is illustrated in the examples set out below.

30 In an exemplary embodiment, the target protein gene is inserted in to the MSCVneo vector (Hawley et al, *supra*) under the control of the viral LTR promoter and also carrying the neomycin phosphotransferase gene as a selectable marker to confer resistance to G418. Helper-free MSCVneo-target protein virus producing packaging cells (Markowitz et al. (1988) *J Virol* 62:1120-1124) can be made by infection of tunicamycin-treated cells with supernatant from transient transfectants according to the methods of 35

Hawley et al. (1991) *Leukemia Res* 15:659-673. The cells are maintained in, e.g., Dulbecco's modified Eagle medium (DMEM) supplemented with G418. Helper-free MSCVneo-target protein viral stocks can be produced by pooling populations of packaging cells with high titre (e.g., $>10^6$ CFU/ml). The retroviral infection may be 5 performed by either including into the culture medium, supernatants (e.g., 5 to 20% vol/vol) produced by the pooled retroviral packaging cell lines, or by culturing the stem cells directly over the infected retroviral packaging lines themselves, or by both. See, for example, U.S. Patents 5,399,493 and 5,399,346 and PCT publication WO 93/07281.

Returning to the general discussion of retroviral vectors, it is noted that the art 10 demonstrates that it is possible to limit the infective spectrum of retroviruses, and consequently of retroviral-based vectors, by modifying the viral packaging proteins on the surface of the viral particle (see, for example PCT publications WO93/25234, WO94/06920, and WO94/11524). For instance, strategies for the modification of the 15 infection spectrum of retroviral vectors include: coupling antibodies specific for stem cell surface antigens to the viral *env* protein (Roux et al. (1989) *PNAS* 86:9079-9083; Julian et al. (1992) *J. Gen Virol* 73:3251-3255; and Goud et al. (1983) *Virology* 163:251-254); or coupling cell surface ligands to the viral *env* proteins (Neda et al. (1991) *J Biol Chem* 266:14143-14146). Coupling can be in the form of the chemical cross-linking with a 20 protein or other variety (e.g. lactose to convert the *env* protein to an asialoglycoprotein), as well as by generating fusion proteins (e.g. single-chain antibody/*env* fusion proteins). This technique, while useful to limit or otherwise direct the infection to certain tissue types, and can also be used to convert an ecotropic vector in to an amphotropic vector.

To further illustrate, the target protein gene construct can be generated using a 25 retroviral vector which further provides a fusion protein including the viral envelope protein and the vesicular stomatitis virus (VSV-G) glycoprotein (Burns et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:8033-37; PCT Patent Application WO 92/14829; and WO 96/09400). Unlike typical amphotropic *env* proteins, the VSV-G protein is thought to 30 mediate viral infection by fusing with a phospholipid component of cell membranes rather than by recognition of a cell surface protein. Since infection is not dependent on a specific receptor, VSV-G pseudotyped vectors have a broad host range. CD34+/Thy-1+ mobilized peripheral blood cells have previously been demonstrated to be transduced with high efficiency by a VSV-G pseudotyped retroviral vector (see Kerr et al. PCT publication WO 96/09400). Genetic modification of the stem cells with a target protein gene construct can 35 be accomplished at any point during their maintenance by transduction with VSV-G pseudotyped virion containing the expression construct.

Moreover, use of retroviral gene delivery can be further enhanced by the use of tissue- or cell-specific transcriptional regulatory sequences which control expression of the recombinant target protein gene.

Another viral gene delivery system useful in the present invention utilizes 5 adenovirus-derived vectors. It has been reported, for example, that adenoviral vectors can be used to transduce human CD34+ hematopoietic cells with high efficiencies. See, for example, Watanabe et al. (1996) *Blood* 87 5032; and Blood Weekly February 10, 1997. The genome of an adenovirus can be manipulated such that it encodes the modified target 10 protein, but is inactive in terms of its ability to replicate in a normal lytic viral life cycle (see, for example, Berkner et al. (1988) *BioTechniques* 6:616; Rosenfeld et al. (1991) *Science* 252:431-434; and Rosenfeld et al. (1992) *Cell* 68:143-155). Suitable adenoviral 15 vectors derived from the adenovirus strain Ad type 5 dl324 or other strains of adenovirus (e.g., Ad2, Ad3, Ad7 etc.) are well known to those skilled in the art. Recombinant adenoviruses are relatively stable and amenable to purification and concentration, and as above, can be modified so as to affect the spectrum of infectivity with respect to stem cell populations.

Additionally, introduced adenoviral DNA (and foreign DNA contained therein) is 20 not integrated into the genome of a host cell but remains episomal, thereby avoiding potential problems that can occur as a result of insertional mutagenesis in situations where introduced DNA becomes integrated into the host genome (e.g., retroviral DNA). Moreover, the carrying capacity of the adenoviral genome for foreign DNA is large (up to 25 8 kilobases) relative to other gene delivery vectors (Berkner et al., *supra*; Haj-Ahmad and Graham (1986) *J. Virol.* 57:267). Most replication-defective adenoviral vectors currently in use and therefore favored by the present invention are deleted for all or parts 30 of the viral E1 and E3 genes but retain as much as 80% of the adenoviral genetic material (see, e.g., Jones et al. (1979) *Cell* 16:683; Berkner et al., *supra*; and Graham et al. in *Methods in Molecular Biology*, E.J. Murray, Ed. (Humane, Clifton, NJ, 1991) vol. 7. pp. 109-127). Expression of the inserted target protein gene can be under control of, for example, the E1A promoter, the major late promoter (MLP) and associated leader sequences, the E3 promoter, or exogenously added promoter sequences.

Yet another viral vector system useful for delivery of the subject target protein genes is the adeno-associated virus (AAV). Adeno-associated viral vectors have been shown to be effective at transducing other genes into pluripotent hematopoietic stem cells 35 *in vitro* (see PCT Application WO 96/08560). Adeno-associated virus is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle. (For a review

see Muzychka et al. *Curr. Topics in Micro and Immunol.* (1992) 158:97-129). It is also one of the few viruses that may integrate its DNA into non-dividing cells, and exhibits a high frequency of stable integration (see for example Flotte et al. (1992) *Am. J. Respir. Cell. Mol. Biol.* 7:349-356; Samulski et al. (1989) *J. Virol.* 63:3822-3828; and 5 McLaughlin et al. (1989) *J. Virol.* 62:1963-1973). Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate. Space for exogenous DNA is limited to about 4.5 kb. An AAV vector such as that described in Tratschin et al. (1985) *Mol. Cell. Biol.* 5:3251-3260 can be used to a recombinant target protein gene into stem cells. A variety of nucleic acids have been introduced into different cell types using AAV vectors 10 (see for example Hermonat et al. (1984) *Proc. Natl. Acad. Sci. USA* 81:6466-6470; Tratschin et al. (1985) *Mol. Cell. Biol.* 4:2072-2081, Wondisford et al. (1988) *Mol. Endocrinol.* 2:32-39, Tratschin et al. (1984) *J. Virol.* 51:611-619; and Flotte et al. (1993) *J. Biol. Chem.* 268:3781-3790).

In addition to viral transfer methods, such as those illustrated above, non-viral 15 methods can also be employed to cause expression of a heterologous target protein gene in transfected stem cells. Most nonviral methods of gene transfer rely on normal mechanisms used by mammalian cells for the uptake and intracellular transport of macromolecules. In preferred embodiments, non-viral gene delivery systems of the present invention rely on endocytic pathways for the uptake of the target protein gene construct by the targeted cell. 20 Exemplary gene delivery systems of this type include liposomal derived systems, poly-lysine conjugates, and artificial viral envelopes.

In a representative embodiment, an expression construct including a target protein gene can be entrapped in liposomes bearing positive charges on their surface (e.g., 25 lipofectins) and (optionally) which are tagged with antibodies against cell surface antigens of the targeted cell population (Mizuno et al. (1992) *No Shinkei Geka* 20:547-551; PCT publication WO91/06309; Japanese patent application 1047381; and European patent publication EP-A43075).

In yet another illustrative embodiment, the gene delivery system comprises an antibody or cell surface ligand which is cross-linked with a gene binding agent such as 30 polylysine (see, for example, PCT publications W093/04701, W092/22635, W092/20316, WO92/19749, and WO92/06180). It will also be appreciated that effective delivery of the subject nucleic acid constructs via receptor-mediated endocytosis can be improved using agents which enhance escape of the gene from the endosomal structures. For instance, whole adenovirus or fusogenic peptides of the influenza HA gene product can be used as 35 part of the delivery system to induce efficient disruption of DNA-containing endosomes

(Mulligan et al. (1993) *Science* 260:926; Wagner et al. (1992) *PNAS* 89:7934; and Christiano et al. (1993) *PNAS* 90:2122).

For example, the target protein gene construct can be used to transfect hematopoietic stem cells using a soluble polynucleotide carrier comprising a ligand to a stem cell receptor (e.g., steel factor) conjugated to a polycation, e.g. polylysine. To further illustrate, the gene delivery system can be targeted specifically to c-kit-expressing cells, e.g. human hematopoietic progenitor cells. The c-kit protein is a tyrosine kinase receptor for steel factor and is expressed on pluripotential stem cells capable of reconstituting all hematopoietic lineages. Furthermore, c-kit expression is restricted to stem/progenitor cells, and is not expressed on their committed progeny except for expression in mast cells. In an illustrative embodiment, the expression vector for the target protein gene is condensed by electrostatic forces with polylysine (PL) which has been covalently linked to streptavidin and PL which has been covalently linked to adenovirus (in order to achieve endosomal lysis). To the vector-PL conjugate is added a biotinylated steel factor which becomes associated with the vector-PL conjugate through the streptavidin-biotin interaction. Using such constructs, hematopoietic stem cells can be targeted for transfection with the target protein gene construct. See, for example, U.S. Patent 5,166,320, and Schwarzenberger et al., *Blood* (1996) 87(2): 472-78). One advantage to the PL-vector construct described above is the ability to carry out transient transfection of stem cell populations, while committed hematopoietic cells will be refractory to the transfection process because of a lack of c-kit. Another advantage to this approach derives from the fact that DNA uptake relies on highly efficient receptor-mediated endocytosis, a physiological pathway for macromolecular uptake not associated with cellular toxicity. However, in other embodiments, the carrier is conjugated with a ligand (or other binding molecule) specific for certain cell lineages, such as T-cells.

The subject target protein gene constructs can be efficiently introduced into stem cells by DNA transfection or by virus-mediated transduction as extensively described above. *In vitro* culturing systems known in the art for stem cells provide an accessible model for genetic manipulations. Possible method of transduction include, but are not limited to, direct co-culture of cells with viral producer cells (see, e.g., Bregni et al. (1992) *Blood* 80: 1418-22). Alternatively, supernatants from virally infected cells can be isolated and applied to cultures of cells under conditions appropriate for infection of the stem cells. See e.g., Xu et al. (1994) *Exp. Hemat.* 22: 223-30; and Hughes et al. (1992). *J. Clin. Invest.* 89:1817. The resulting transduced cells may then be grown under conditions similar to those for unmodified stem cells, whereby the modified stem cells may be expanded and caused to differentiate.

The invention also encompasses genetically engineered cells containing and/or expressing any of the constructs described herein, particularly a construct encoding a receptor, including prokaryotic and eucaryotic cells and in particular, yeast, worm, insect, mouse or other rodent, and other mammalian cells, including human cells, of various types 5 and lineages, whether frozen or in active growth, whether in culture or in a whole organism containing them. Several examples of such engineered cells are provided in the Examples which follow.

At present it is especially preferred that the cells be mammalian cells, particularly primate, more particularly human, but can be associated with any animal of interest, 10 particularly domesticated animals, such as equine, bovine, murine, ovine, canine, feline, *etc.* Among these species, various types of cells can be involved, such as hematopoietic, neural, mesenchymal, cutaneous, mucosal, stromal, muscle, spleen, reticuloendothelial, epithelial, endothelial, hepatic, kidney, gastrointestinal, pulmonary, *etc.* Of particular interest are hematopoietic cells, which include any of the nucleated cells which may be 15 involved with the lymphoid or myelomonocytic lineages. Of particular interest are members of the T- and B-cell lineages, macrophages and monocytes, myoblasts and fibroblasts. Also of particular interest are stem and progenitor cells, such as hematopoietic neural, stromal, muscle, hepatic, pulmonary, gastrointestinal, *etc.*

The cells can be autologous cells, syngeneic cells, allogenic cells and even in some 20 cases, xenogeneic cells. The cells may be modified by changing the major histocompatibility complex ("MHC") profile, by inactivating β_2 -microglobulin to prevent the formation of functional Class I MHC molecules, inactivation of Class II molecules, providing for expression of one or more MHC molecules, enhancing or inactivating cytotoxic capabilities by enhancing or inhibiting the expression of genes associated with 25 the cytotoxic activity, or the like.

In some instances specific clones or oligoclonal cells may be of interest, where the cells have a particular specificity, such as T cells and B cells having a specific antigen specificity or homing target site specificity.

Likewise, this invention encompasses any non-human organism containing such 30 genetically engineered cells. To illustrate this aspect of the invention, an example is provided of a mouse containing engineered cells expressing, in a ligand-dependent manner, an introduced target gene linked to a nucleotide sequence recognized by a transcriptional activator of the invention.

IV. Sources of Cells

Those skilled in the art will appreciate that the subject method can be carried out either in *in vivo* or *ex vivo* (e.g., in cell culture) embodiments. The *in vivo* delivery of a hematopoietic gene construct can be carried out using any of a variety of gene therapy techniques. For *ex vivo* applications, the stem cell to be genetically modified must first be isolated in cell culture. A variety of protocols for isolating embryonic and/or hematopoietic stem cells are well known in the art. Exemplary stem cell cultures for use in the subject method are described below.

10 *A. Isolation of Hematopoietic Stem Cells*

Hematopoietic stem cells (HSCs) can be isolated from a mammalian source including, but not limited to, bone marrow (both adult and fetal), mobilized peripheral blood (MPB), umbilical cord blood and/or fetal liver. In a preferred embodiment, the HSCs are obtained from the subject into which the stem cells are to be transplanted after *in vitro* culturing and transduction of the hematopoietic gene construct.

The source of cells for the present invention can be, in addition to humans, non-human mammals. A variety of protocols are known in the art for isolating both embryonic stem cells and hematopoietic stem cells from non-human animals. See, for example, the Wheeler U.S. Patent 5,523,226 entitled "Transgenic swine compositions and methods" and the Emery et al. PCT publication WO 95/13363 entitled "Hematopoietic Stem Cells From Swine Cord Blood And Uses Thereof". The preferred non-human animals include vertebrates such as rodents, non-human primates, sheep, dog, cow and pigs. The term "non-human mammal" refers to all members of the class *Mammalia* except humans.

Where the intended use of the resulting hematopoietic cell is for implantation in human patients, the cells derived from transgenic animals can be used as a source for "humanized" hematopoietic cells, e.g., for xenogenic grafting into human subjects. For example, as described by the Sachs et al. PCT publication WO 96/06165 entitled "Genetically Engineered Swine Cells", the art provides for implantation of swine donor cells which have been engineered to increase desirable interactions between the donor cells and molecules and cells of a recipient, e.g., to promote the engraftment or function of the donor stem cells in the recipient environment. To illustrate, the cells can be engineered to express a human adhesion molecule, e.g., an adhesion molecule involved in engraftment and/or maintenance of hematopoietic cells. Examples of human adhesion molecules include VLA-4, c-kit, LFA-1, CD11a, Mac-1, CR3, CD11b, p150, p95, CD11c, CD49a,

RECORDED IN U.S. PATENT AND TRADEMARK OFFICE

LPAM-1, CD49d, CD44, CD38, and CD34. The transgenic cells can also be engineered to minimize unwanted interactions between the donor cells and molecules and cells of the recipient which, e.g., promote the rejection of donor graft cells or which inhibit the function of the donor graft cells. For example, the donors cells can be derived from a 5 transgenic animal expressing one or more human MHC polypeptides.

Bone marrow cells can be obtained from a source of bone marrow, including but not limited to, ilium (e.g. from the hip bone via the iliac crest), tibia, femora, spine, or other bone cavities. Other sources of stem cells include, but are not limited to, embryonic yolk sac, fetal liver, and fetal spleen.

10 For isolation of bone marrow, an appropriate solution can be used to flush the bone, e.g., a salt solution supplemented with fetal calf serum (FCS) or other naturally occurring factors, in conjunction with an acceptable buffer at low concentration, generally from about 5-25 mM. Convenient buffers include HEPES, phosphate buffers and lactate buffers. Otherwise bone marrow can be aspirated from the bone in accordance with 15 conventional techniques.

Methods for mobilizing stem cells into the peripheral blood are known in the art and generally involve treatment with chemotherapeutic drugs, cytokines (e.g. GM-CSF, G-CSF or IL3), or combinations thereof. Typically, apheresis for total white cells begins when the total white cell count reaches 500-200 cells/l and the platelet count reaches 20 50,000/l.

Various techniques can be employed to separate the cells by initially removing lineage committed cells. Monoclonal antibodies are particularly useful for identifying markers associated with particular cell lineages and/or stages of differentiation. The antibodies can be attached to a solid support to allow for crude separation. The separation 25 techniques employed should maximize the retention of viability of the fraction to be collected. Various techniques of different efficacy can be employed to obtain "relatively crude" separations. Such separations are where up to 10%, usually not more than about 5%, preferably not more than about 1%, of the total cells present not having the marker can remain with the cell population to be retained. The particular technique employed will 30 depend upon efficiency of separation, associated cytotoxicity, ease and speed of performance, and necessity for sophisticated equipment and/or technical skill.

The use of separation techniques include, but are not limited to, those based on differences in physical (density gradient centrifugation and counter-flow centrifugal elutriation), cell surface (lectin and antibody affinity), and vital staining properties 35 (mitochondria-binding dye rho123 and DNA-binding dye Hoechst 33342). Procedures for

separation can include, but are not limited to, magnetic separation, using antibody-coated magnetic beads, affinity chromatography, cytotoxic agents joined to a monoclonal antibody or used in conjunction with a monoclonal antibody, including, but not limited to, complement and cytotoxins, and "panning" with antibody attached to a solid matrix, e.g., 5 plate, elutriation or any other convenient technique. Techniques providing accurate separation include, but are not limited to, FACS, which can have varying degrees of sophistication, e.g., a plurality of color channels, low angle and obtuse light scattering detecting channels, impedance channels, etc.

A large proportion of the differentiated cells can be removed by initially using a 10 relatively crude separation, where major cell population lineages of the hematopoietic system, such as lymphocytic and myelomonocytic, are removed, as well as minor populations, such as megakaryocytic, mast cells, eosinophils and basophils. Usually, at least about 70 to 90 percent of the hematopoietic cells will be removed. If desired, a prior 15 separation can be employed to remove erythrocytes, by employing Ficoll-Hypaque separation.

The gross separation can be achieved using methods known in the art including, but not limited to, magnetic beads, cytotoxic agents, affinity chromatography or panning. Antibodies which find use include antibodies to lineage specific markers which allow for removal of most, if not all, mature cells, while being absent on stem cells.

20 Concomitantly or subsequent to a gross separation, which provides for positive selection, a negative selection can be carried out, where antibodies to lineage-specific markers present on dedicated cells are employed. For the most part, these markers include, but are not limited to, CD2-, CD3-, CD7-, CD8-, CD10-, CD14-, CD15-, CD16-, CD19-, CD20-, CD33- and glycophorin A; preferably including, but not limited to, at least 25 CD2-, CD14-, CD15-, CD16-, CD19- and glycophorin A; and normally including at least CD14- and CD15-. As used herein, Lin refers to a cell population lacking at least one lineage-specific marker. The hematopoietic cell composition substantially depleted of dedicated cells can then be further separated using a marker for Thy-1, whereby a substantially homogeneous stem cell population is achieved. Exemplary of this stem cell 30 population is a population which is CD34+Thy-1+Lin-, which provides an enriched stem cell composition. Other markers that have been reported to subdivide CD34+ cells, further enriching for stem cells include, but are not limited to, CD38-, rhodamine lo, c-kit receptor, HLA DR lo/-, CD71, and CD45 RA-. In fetal tissues and umbilical cord, stem cells are highly enriched in the CD34 hiLin- populations as described by Giusto et al. 35 (1993) Blood 84: 421-32.

The purified stem cells have low side scatter and low to medium forward scatter profiles by FACS analysis. Cytospin preparations show the enriched stem cells to have a size between mature lymphoid cells and mature granulocytes. Cells can be selected based on light-scatter properties as well as their expression of various cell surface antigens.

5 While it is believed that the particular order of separation is not critical to this invention, the order indicated is preferred. Preferably, cells are initially separated by a coarse separation, followed by a fine separation, with positive selection of a marker associated with stem cells and negative selection for markers associated with lineage committed cells.

10 Compositions highly enriched in stem cells can be achieved in this manner. The desired stem cells are exemplified by a population with the CD34+Thy-1+Lin- phenotype and being able to provide for cell regeneration and development of members of all of the various hematopoietic lineages.

15 It should be noted that negative selection lineage selection for lineage specific markers provide a greater enrichment in stem cells obtained from bone marrow than from MPB. The majority of CD34 cells that are mobilized into the peripheral blood do not express lineage-specific markers and, therefore, Lin selection does not significantly enrich over CD34 selection in the peripheral blood as it does in bone marrow. Selection for Thy-1+ does enrich for stem cells in both mobilized peripheral blood and bone marrow.

20 Fetal or neonatal blood are also sources for the hematopoietic stem and progenitor cells of the present invention.

25 Fetal blood can be obtained by any method known in the art. For example, fetal blood can be taken from the fetal circulation at the placental root with the use of a needle guided by ultrasound (Daffos et al., (1985) *Am. J. Obstet Gynecol* 153:655-660; Daffos et al., (1983) *Am. J. Obstet. Gynecol.* 146:985), by placentocentesis (Valenti, C., (1973) *Am. J. Obstet. Gynecol.* 115:851; Cao et al., (1982) *J. Med. Genet.* 19:81), by fetoscopy (Rodeck, C.H., (1984) in Prenatal Diagnosis, Rodeck, C.H. and Nicolaides, K.H., eds., Royal College of Obstetricians and Gynaecologists, London), etc.

30 In a preferred embodiment of the invention, neonatal hematopoietic stem and progenitor cells can be obtained from umbilical cord blood and/or placental blood. The use of cord or placental blood as a source of hematopoietic cells provides numerous advantages. Cord blood can be obtained easily and without trauma to the donor. In contrast, at present, the collection of bone marrow cells is a traumatic experience which is costly in terms of time and money spent for hospitalization. Cord blood cells can be used 35 for autologous transplantation, when and if needed, and the usual hematological and

immunological problems associated with the use of allogeneic cells, matched only partially at the major histocompatibility complex or matched fully at the major, but only partially at the minor complexes, are alleviated.

Collections should be made under sterile conditions. Immediately upon collection,
5 the neonatal or fetal blood should be mixed with an anticoagulant. Such an anticoagulant can be any known in the art, including but not limited to CPD (citrate-phosphate-dextrose), ACD (acid citrate-dextrose), Alsever's solution, De Gowin's Solution, Edglugate-Mg, Rous-Turner Solution, other glucose mixtures, heparin, ethyl bisoumacetate, etc. (See Hurn, B.A.L., 1968, Storage of Blood, Academic Press, New
10 York, pp. 26-160).

B. Isolation of Embryonic Stem Cells

The present system is based on the ability of ES cells to differentiate and generate hematopoietic cells in culture and *in vivo*. Previous studies have demonstrated that ES
15 cells will differentiate in culture and generate multiple hematopoietic lineages. However, in most of these studies, the extent of hematopoietic development has been limited and variable, and the exact kinetics of hematopoietic differentiation has been unpredictable or poorly defined. Utilizing the subject method, hematopoietic stem cells can be generated by ectopic expression of a hematopoietic gene such as *LH-2*. The advantages of such a
20 system are several-fold. First, one has access to the cells at all stages of differentiation, making it possible to manipulate the system as it develops. Second, an *in vitro* system based on ES cells will enable one to study the function of a broad spectrum of genes through inactivation by homologous recombination without encountering the problems inherent to an *in vivo* system; namely, embryonic lethaliies.

25 Embryonic stem cells are generated and maintained using methods well known to the skilled artisan such as those described by Doetschman et al. (1985) *J. Embryol. Exp. Morphol.* 87:27-45). Any line of ES cells can be used, however, the line chosen is typically selected for the ability of the cells to differentiate into embryoid bodies (EB) followed by their commitment into hematopoietic lineages, e.g. erythroid, lymphoid,
30 myeloid. Thus, any ES cell line from human or non-human origin that is believed to have this capability is suitable for use herein. As an example of one mouse strain that is typically used for production of ES cells, is the 129J strain, e.g. cell line CCE utilized in the Examples below. Still another preferred murine cell line is the cell line J1. Other ES cell lines include D3 (American Type Culture Collection, catalog no. CCL 1934) and the
35 WW6 cell line (see Ioffe et al. (1995) *PNAS* 92:7357-7361).

ES cells are cultured using methods well known to the skilled artisan, such as those set forth by Robertson in: *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E.J. Robertson, ed. IRL Press, Washington, D.C. [1987]); by Bradley et al. (1986) *Current Topics in Devel. Biol.* 20:357-371); and by Hogan et al. (Manipulating the 5 Mouse Embryo: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY [1986]). As an illustration, ES cells can be grown and passaged *in vitro* with or without feeder layers, e.g., embryonic fibroblasts, in the presence of growth factors selected from steel factor (membrane -associated or soluble forms), leukemia inhibitory factor (LIF) and fibroblast growth factor (FGF). See e.g., US Pat No. 5,453,357. Growth 10 and differentiation enhancing concentrations of these factors can range from 0.5-500 ng/ml, preferably, 10-20 ng/ml. Differentiation of ES cells into embryoid bodies (EBs) and multiple cell-types, e.g., hematopoietic, endothelial, muscle and neuronal lineages, can be achieved by a number of standard methods known in the art (reviewed in G. Keller, Current Opinion: 862-69; see also, G. Keller et al. *MCB* 13(1) 473-86).

15 The technique most frequently used to differentiate ES cells is simply to remove the cells from contact with the feeder cells, or from the presence of LIF, and culture them in liquid or methyl cellulose containing media in bacterial grade petri dishes. Under these conditions, ES cells are unable to adhere to the surface of the dish, and the formation of EBs is enhanced. A modification of this method to maximize ES cell differentiation into 20 hematopoietic lineages involves the culturing of these cells on stromal cells, which provides a supportive environment for hematopoietic cells as they develop within the EBs. Stromal cell culturing methods are extensively described below in *Expansion and Differentiation of Genetically Modified Cells*. Once EBs are formed, they can be dissociated into a single cell suspension. The generated EBs can be assayed at various 25 stages of development for the presence of specific cell populations. For example, hematopoietic lineages can be examined by plating EB-derived cells in methyl cellulose in the presence of growth factors for determining hematopoietic precursor populations. A specific illustration of precursor cell assay is provided in the Examples below. In brief, single cell suspension of EBs can be assayed for precursor content in colony forming cell- 30 culture (CFC-c) assay as described in Keller et al., *supra*. This procedure will be hereinafter referred to as the precursor assays. Alternatively, EB-derived cells can be analyzed for the presence of specific cell-surface antigens (e.g., immunoglobulin can be used to stain B lymphocytes) by immunocytochemical methods or by FACS analysis. The most stringent test for the differentiation potential of these cells involves the ability of 35 dissociated EB cells to repopulate the hematopoietic system of a recipient animal. Detection of cell surface antigens and transplantation protocols are extensively described

below in the section entitled "*Expansion and Differentiation of Genetically Modified Cells*".

5 V. Methods of the invention

The invention provides methods for inducing a specific biological activity in a tissue specific manner. In a preferred embodiment, the invention provides a method for modulating cell growth, differentiation and/or survival. According to the method of the invention, a cell is modified to express a modified form of a target protein which mediates 10 the desired biological activity, said target protein interacting specifically with a modified form of a ligand of the target protein, which essentially does not interact with the wild-type target protein.

In a preferred embodiment of the invention, the target protein is a protein involved in the Ca²⁺/calcineurin pathway, which is involved, in particular in activation of 15 lymphocytes, e.g., T lymphocytes. In an even more preferred embodiment, the target protein is a protein which forms a ternary complex with calcineurin or FRB. Even more preferably, the target protein is cyclophilin, FKBP12, or FRB. Calcineurin is present in most tissues, with the highest level of expression being present in the brain. In lymphocytes, in particular in T cell, calcineurin is involved in activation of the T cells in 20 the presence of Ca²⁺. Thus, the invention provides a method for regulating T cell activation, e.g., inducing tolerance, without significantly affecting biological activities mediated by calcineurin in other cell types. For example, a population of cells can be engineered to express a modified cyclophilin selectively in T cells, such as by operably linking the gene encoding the modified cyclophilin molecule to a promoter that activates 25 transcription specifically in T cells, e.g., CD4 promoter. Only the T cells will express the modified cyclophilin and therefore be responsive to the modified ligand. Thus, upon contact with the modified ligand, activation of the T cells expressing the modified cyclophilin will be inhibited, without inducing toxic effects in the cells which do not express the modified cyclophilin.

30 Furthermore, it has been observed that a reduction in calcineurin activity by only 50% significantly impairs signaling by the antigen receptor on T cells. Similarly, patients treated for transplant rejection have only a 50% reduction in calcineurin activity at the therapeutic concentration of the drug, though they do not usually reject the transplant. In addition, cyclosporin appears to induce tolerance to transplanted tissue even after the drug 35 is withdrawn. For example, in the case of bone marrow populated largely by the

transplanted cells, while the lymphocyte population is derived largely or in part from the recipient. Thus, this indicates that blockage of calcineurin action by only 50% for long periods of time results in the development of tolerance to transplanted tissue. Parallel studies in mice have also suggested that these drugs are capable of inducing long term
5 tolerance of transplanted tissues.

Accordingly, the invention is useful in any situation in which tolerance of T lymphocytes is desired. The invention can be applied in vitro or in vivo. In a preferred embodiment, the method is used on cells, e.g., cells obtained from a subject, the cells are modified in vitro and then administered to the subject. In another embodiment, the cells
10 are modified in vivo to express a modified target protein. Conditions which can be treated according to the method of the invention include those involving an immune reaction and are further described below.

In one embodiment, this invention is directed to a method for preventing graft rejection or for treating host versus graft disease following blood marrow transplantation.
15 In one embodiment, the invention, comprises the following steps: (a) inserting DNA encoding a modified cellular target protein, e.g., cyclophilin specific for a modified cyclosporin into a hematopoietic stem cell to produce a transformed hematopoietic stem cell; (b) introducing the transformed hematopoietic stem cell into a recipient mammal, such that the modified cellular target protein cyclophilin is expressed; and,
20 (c) administering an effective amount of the modified cyclosporin to the recipient mammal. As used herein, the term "hematopoietic stem cell" refers to a cell that is capable of developing into mature myeloid and/or lymphoid cells. The method of this invention avoids the undesirable side effect of broad spectrum immune suppressants which are often used in transplantation. The genetic engineering techniques for cloning a protein,
25 transfecting a cell, and introducing the transfected cell into a patient in gene therapy are known. One of skill in this art can determine through routine experimentation the preferred cloning techniques, transfection methods and gene delivery protocol to be used.

In a preferred embodiment, this invention is directed to the modified cyclosporin drug, CpSar11-CsA, which can be administered to the patient receiving the transformed
30 hematopoietic stem cells that are capable of expressing the modified cellular target protein cyclophilin CypAgtm and directed to the modified target protein cyclophilin with the alterations in its amino acid sequence making it specific for the modified cyclosporin CpSar11-CsA.

In another embodiment, the invention is used for treating autoimmune disorders by
35 inducing tolerance of autoimmune cells. Immunosuppressive drugs remain the cornerstone of therapy for autoimmune disorders, although their efficacy is limited and

their chronic use entails considerable risk. Immunosuppressive treatment is particularly indicated for progressive neurologic disability without remission when the patient is on a rapidly progressive course. The invention provides a method for treating autoimmune diseases without incurring such risks and toxic effects.

5 The method according to this invention includes (a) inserting DNA encoding a modified cellular target protein, for example a modified cyclophilin target protein, specific for a modified ligand, cyclosporin, into a T cell to produce a transformed T cell; (b) introducing the transformed T cell into a patient suffering from an autoimmune disorder, such that the modified target protein is expressed, and then, (c) administering to 10 the patient an effective amount of a modified immune agent whose target protein is the modified target protein. In this type of application, specific populations of T cells are transfected and regulated by the modified drug, for example, cyclosporin A. It is preferable that a significant amount of cells are transformed. This can be achieved, by 15 viral transformation, as further described herein. Alternatively, cells can be targeted and transformed in vivo with a construct encoding the modified target protein.

One exemplary autoimmune disease which can be treated according to the method of the invention is multiple sclerosis. Multiple sclerosis (MS) is characterized by chronic inflammation, demyelination, and gliosis (scarring). MS affects 350,000 Americans and is, with the exception of trauma, the most frequent cause of neurologic disability in early 20 to middle adulthood. Indirect evidence supports an autoimmune etiology for MS, perhaps triggered by a viral infection in a genetically susceptible host.

T cells reactive against myelin proteins, either myelin basic protein (MBP) or myelin proteolipid protein (PLP), mediate CNS inflammation in experimental allergic encephalomyelitis (EAE), a laboratory model for demyelinating diseases. This has been 25 proven by adoptive transfer experiments in which sensitized T cells from an animal with EAE can transfer disease to a healthy syngeneic recipient.

It is possible that tissue damage in MS is mediated by cytokine products of activated T cells, macrophages, or astrocytes.

According to this invention, one method of treating MS, particularly in those 30 patients where MS has become life-threatening, is to administer a genetically engineered T cell that expresses a modified target protein for a modified immune agent, such as cyclosporin, FK506, and rapamycin and then administering the modified immunosuppressive drug.

Another exemplary autoimmune disease which can be treated according to the 35 method of the invention is Systemic Lupus Erythematosus (SLE). SLE is a disease of unknown cause in which tissues and cells are damaged by pathogenic autoantibodies and

immune complexes. In the United States, the prevalence of SLE in urban areas varies from 15 to 50 per 100,000 population.

SLE probably results from interactions between susceptibility genes and the environment. This interaction results in abnormal immune responses with T and B 5 lymphocyte hyperactivity which is not suppressed by the usual immunoregulatory circuits.

Life threatening, severely disabling manifestations of SLE that are responsive to immunosuppression can be treated according to this invention by administering a genetically engineered T cell that expresses a modified target protein for a modified immune agent and then administering the modified immunosuppressive drug, such as 10 cyclosporin, FK506, or rapamycin.

In addition to autoimmune diseases and graft versus host disease, undesired T cell activation may give rise to a variety of other diseases or conditions, e.g., allograft rejection, hypersensitivity, delayed-type hypersensitivity mediated conditions, and allergic reactions, e.g. drug allergies. Yet other diseases or disorders that can be treated according 15 to the method of the invention include asthma, allergic diseases that have manifestations of inflammations such as dermatitis or rhinitis, for example, atopic dermatitis, symptoms such as bronchoconstriction accompanied by asthma, allergic diseases, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, other arthritic conditions, septic shock, sepsis, and endotoxic shock, atrophic gastritis, thyroiditis, allergic encephalomyelitis, 20 gastric mucosa, thyrotoxicosis, autoimmune hemolytic anemia, thyroidosis, scleroderma, diabetes mellitus, Graves' disease, and sympathetic ophthalmia (Eisen, H. N., 1979, Immunology, Harper and Row, Hagerstown, Md., pp. 557-595).

Another application according to this invention is the selective activation of pathways in cells through receptor-ligand interactions. Thus, a therapeutic protein of 25 choice can be selectively modified to bind with its mutant receptor, which will not bind with other unmodified receptors of "wild-type" or "normal" type, and thus activate the pathway.

For example, the following proteins have known structures and may be modified according to this invention to selectively activate a mutant target protein: human insulin, 30 used in treating diabetes mellitus; human growth hormone, used in treating growth hormone deficiency in children; interferon-*alpha*, used to treat hairy cell leukaemia and chronic hepatitis A and C; tissue-type plasminogen activator (tPA), used to treat myocardial infarction; erythropoietin, used to treat anaemia in chronic renal failure; granulocyte colony-stimulating factor (G-CSF), used to treat neutropenia following cancer 35 chemotherapy; granulocyte-macrophage colony-stimulating factor (GM-CSF), used for

myeloid reconstitution after bone marrow transplantation; and, Factor VIII used in treating haemophilia A.

In another embodiment, the invention can be used to treat neurologic diseases or conditions. For example, in certain conditions, e.g., degenerative diseases, it is desirable 5 to regenerate neurons or other cells of the nervous system, e.g., by implantation of such cells. According to the method of the invention, the growth and/or differentiation of such cells could be controlled, by genetically engineering the cells to express a modified target protein involved in growth, differentiation or cell death control. Methods of genetically modifying donor cells by gene transfer for grafting into the central nervous system to treat 10 defective, diseased or damaged cells are disclosed in U.S. Pat. No. 5650148 by Gage et al. The modified donor cells produce functional molecules that effect the recovery or improved function of cells in the CNS. Methods and vectors for carrying out gene transfer and grafting are also described in U.S. Pat. No. 5650148.

Alternatively, this invention can be used to engineer ligand-inducable cell death 15 characteristics into cells. Such engineered cells can then be eliminated from a cell culture after they have served their intended purpose (e.g. production of a desired protein or other product) by adding the ligand to the medium. Engineered cells of this invention can also be used *in vivo*, to modify whole organisms, preferably animals, including humans, e.g. such that the cells produce a desired protein or other result within the animal containing 20 such cells. Such uses include gene therapy.

In one embodiment of the invention, cells are modified *ex vivo* and introduced into a subject. Depending upon the nature of the cells, the cells may be introduced into a host 25 organism, e.g. a mammal, in a wide variety of ways. Hematopoietic cells may be administered by injection into the vascular system, there being usually at least about 10^4 cells and generally not more than about 10^{10} , more usually not more than about 10^8 cells.

The number of cells which are employed will depend upon a number of circumstances, the purpose for the introduction, the lifetime of the cells, the protocol to be used, for example, the number of administrations, the ability of the cells to multiply, the stability of the therapeutic agent, the physiologic need for the therapeutic agent, and the like.

30 Alternatively, with skin cells which may be used as a graft, the number of cells would depend upon the size of the layer to be applied to the burn or other lesion. Generally, for myoblasts or fibroblasts, the number of cells will at least about 10^4 and not more than about 10^8 and may be applied as a dispersion, generally being injected at or near the site of interest. The cells will usually be in a physiologically-acceptable medium.

35 Instead of *ex vivo* modification of the cells, in many situations one may wish to modify cells *in vivo*. For this purpose, various techniques have been developed for

modification of target tissue and cells *in vivo*. A number of virus vectors have been developed, such as adenovirus and retroviruses, which allow for transfection and random integration of the virus into the host. See, for example, Dubensky et al. (1984) Proc. Natl. Acad. Sci. USA 81, 7529-7533; Kaneda et al., (1989) Science 243,375-378; Hiebert et al. 5 (1989) Proc. Natl. Acad. Sci. USA 86, 3594-3598; Hatzoglu et al. (1990) J. Biol. Chem. 265, 17285-17293 and Ferry, et al. (1991) Proc. Natl. Acad. Sci. USA 88, 8377-8381. The vector may be administered by injection, e.g. intravascularly or intramuscularly, inhalation, or other parenteral mode.

In accordance with *in vivo* genetic modification, the manner of the modification 10 will depend on the nature of the tissue, the efficiency of cellular modification required, the number of opportunities to modify the particular cells, the accessibility of the tissue to the DNA composition to be introduced, and the like. By employing an attenuated or modified retrovirus carrying a target transcriptional initiation region, if desired, one can activate the 15 virus using one of the subject transcription factor constructs, so that the virus may be produced and transfect adjacent cells.

The DNA introduction need not result in integration in every case. In some situations, transient maintenance of the DNA introduced may be sufficient. In this way, one could have a short term effect, where cells could be introduced into the host and then turned on after a predetermined time, for example, after the cells have been able to home 20 to a particular site.

Tissue specific expression of the modified target protein of the invention can also be achieved by selectively introducing a vector encoding the modified target protein in the desired cell type. This can be achieved by various methods. For example, one can choose a viral vector which specifically infects the desired cell type. Alternatively, one can use 25 liposomes, bacteria, or other form of delivery vehicle that can be targeted to the desired cell type by linking to the delivery vehicle a ligand that interacts specifically with the desired cell. The ligand can be a protein, e.g., a growth factor, which interacts with a growth factor target protein on the target cells. In a preferred embodiment, the ligand is altered such that it does not induce a biological activity, but only serves as a target 30 molecule for the construct of the invention. The ligand can be an antibody, specifically recognizing an epitope on the desired target cell. Numerous antibodies to surface molecules are available commercially. Alternatively, antibody molecules can also be prepared according to methods known in the art.

The modified ligand providing for activation of the modified target protein may be 35 administered as desired. Depending upon the binding affinity of the modified ligand, the response desired, the manner of administration, the half-life, the number of cells present,

various protocols may be employed. The modified ligand may be administered parenterally or orally. The number of administrations will depend upon the factors described above. The modified ligand may be taken orally as a pill, powder, or dispersion; buccally; sublingually; injected intravascularly, intraperitoneally, subcutaneously; by 5 inhalation, or the like. The modified ligand (and monomeric compound) may be formulated using conventional methods and materials well known in the art for the various routes of administration. The precise dose and particular method of administration will depend upon the above factors and be determined by the attending physician or human or animal healthcare provider. For the most part, the manner of administration will be 10 determined empirically.

The particular dosage of the modified ligand for any application may be determined in accordance with the procedures used for therapeutic dosage monitoring, where maintenance of a particular level of expression is desired over an extended period of times, for example, greater than about two weeks, or where there is repetitive therapy, 15 with individual or repeated doses of ligand over short periods of time, with extended intervals, for example, two weeks or more. A dose of the modified ligand within a predetermined range would be given and monitored for response, so as to obtain a time-expression level relationship, as well as observing therapeutic response. Depending on the levels observed during the time period and the therapeutic response, one could provide a 20 larger or smaller dose the next time, following the response. This process would be iteratively repeated until one obtained a dosage within the therapeutic range. Where the modified ligand is chronically administered, once the maintenance dosage of the ligand is determined, one could then do assays at extended intervals to be assured that the cellular system is providing the appropriate response and level of the expression product.

25 It should be appreciated that the system is subject to many variables, such as the cellular response to the ligand, the efficiency of expression and, as appropriate, the level of secretion, the activity of the expression product, the particular need of the patient, which may vary with time and circumstances, the rate of loss of the cellular activity as a result of loss of cells or expression activity of individual cells, and the like. Therefore, it is 30 expected that for each individual patient, even if there were universal cells which could be administered to the population at large, each patient would be monitored for the proper dosage for the individual.

The subject methodology and compositions may be used for the treatment of a wide variety of conditions and indications. For example, B- and T-cells may be used in 35 the treatment of cancer, infectious diseases, metabolic deficiencies, cardiovascular disease, hereditary coagulation deficiencies, autoimmune diseases, joint degenerative diseases, *e.g.* arthritis, pulmonary disease, kidney disease, endocrine abnormalities, *etc.* Various cells

involved with structure, such as fibroblasts and myoblasts, may be used in the treatment of genetic deficiencies, such as connective tissue deficiencies, arthritis, hepatic disease, *etc.*

VI Kits

This invention further provides kits useful for the foregoing applications. One such kit contains one or more nucleic acids encoding a modified target protein thereof. The kit preferably also contains a modified ligand for the target protein. Thus, in one 5 embodiment, the kit comprises a vector containing a gene encoding a modified cyclophilin molecule operably linked to a promoter expressed specifically in T cells and a modified cyclophilin molecule.

10 The contents of all cited references including literature references, issued patents, published patent applications and co-pending patent applications, as cited throughout this application are hereby expressly incorporated by reference.

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
JULY 1998


EXAMPLES

Example 1: Synthesis of a modified Cyclosporin A, CpSar11-CsA

This Example describes the synthesis of a modified form of Cyclosporin A, termed CpSar11-CsA, which does not significantly interact with the wild-type receptor of cyclosporin A, cyclophilin.

As shown below in Scheme 1, the synthesis of CpSar11-CsA first required the asymmetric synthesis of *alpha*-cyclopentyl sarcosine using a combination of the methods of Evans, et al. (*J. Am. Chem. Soc.* 112: 4011-4030 (1990)) and Dorow, et al. (*J. Org. Chem.* 60: 4986-7 (1995)) and the subsequent incorporation of this unnatural amino acid into the CsA macrocycle.

Scheme 1



In the synthesis, HZN-nonaapeptied ($\text{H}_2\text{N-Abu-Sar-MeLeu-Val-MeLeu-Ala-DAla-MeLeu-MeLeu-(Ac-N-MeValinol ester)}$) was synthesized from CsA. The reagent abbreviations include the following: DCM, dichloromethane; DMF, dimethylformamide; KHMDS, 5 potassium hexamethyldisilazide; Trisyl-N₃, triisopropylbenzenesulfonylazide; THF, tetrahydrofuran; Fmoc-CL, 9-fluorenylmethylchloroformate; Boc, t-butyloxycarbonyl; TFA, trifluoroacetic acid; PyBrop, bromo-trispyrrolidinophosphonium hexafluorophosphate; DIEA, diisopropylethylamine; dimedone, 5,5-dimethyl-1,4-cyclohexanedione; PyAop, 7-azabenzotriazo-1-yl-oxy(trispyrrolidino)phosphonium 10 hexafluorophosphate.

The details of the synthesis are set forth below.

CONFIDENTIAL - FOR INTERNAL USE ONLY

N- α -cyclopentylacetyl-4S-benzyloxazolidinone (1)

To a solution of cyclopentylacetic acid (4.94 g, 38.51 mmol) and DMF (one drop) in DCM (100 mL), oxalylchloride (23.1 mL, 2.0 M in DCM, 1.2 eq, 46.2 mmol) was added dropwise over one hour at room temperature. The reaction was stirred for another two hours, evaporated under reduced pressure and dried under vacuum to afford crude cyclopentylacetyl chloride. This residue was dissolved in THF (80 mL) and cooled to -78°C. To a solution of 4S-benzyloxazolidinone (6.79 g, 38.5 mmol) in THF (50 mL) at -78°C, nBuLi (26.2 mL, 1.45 M, 38 mmol) was added dropwise by syringe and stirred for an additional 15 minutes producing lithiated oxazolidinone. This solution was added over 30 minutes via cannula to the solution of cyclopentylacetyl chloride. The reaction mixture was stirred 30 minutes at -78°C before quenching with 1 M NaH₂SO₄ (75 mL). The THF was removed under reduced pressure and the aqueous layer was extracted with DCM (3 x 75 mL). The combined organics were washed with 10% NaHCO₃ aq.(50 mL), brine (50 mL), dried over Na₂SO₄, filtered and evaporated onto silica (15 g). The product was purified by chromatography (silica gel, 5-20% EtOAc in hexanes) to give 7.97g (70 %) of a white solid: $[\alpha]^{20}_D = +52.0^\circ$ (c 1, CHCl₃); IR (film) 2948, 2835, 1779, 1696, 1455, 1383, 1352, 1210, 1099, 700 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.2-7.4 (m, 5H), 4.67 (m, 1H), 4.16, (M, 2H), 3.30 (dd, J= 3.3, 13.3, 1H), 3.02 (dd, J = 6.9, 16.6, 1H), 2.90 (dd, J = 7.4, 16.6, 1H), 2.77 (dd, J = 9.7, 13.3, 1H), 2.33 (m, 1H), 1.89 (m. 2H), 1.62 (m, 4H), 1.22 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 172.9, 153.4, 135.3, 127.2, 66.0, 55.1, 41.3, 37.9, 35.7, 32.44, 32.38, 24.9; HRMS (CI+, NH₃) calc'd for C₁₇H₂₁NO₃: 305.1865, found 305.1870.

2S- α -azido- α -cyclopentylacetyl-4S-oxalolidinone (2)

To THF (40 mL) at -78°C, potassium hexamethyldisilazide (16.6 mL, 0.91 M in toluene, 1.1 eq. 15.1 mmol) was added and stirred for 10 minutes. A pre-cooled (-78°C) solution of N- α -cyclopentylacetyl-4S-benzyloxazolidinone 1 (3.94 g, 13.7 mmol) in THF (40 mL) was added and stirred for 30 minutes and followed by a pre-cooled (-78°C) solution of Trisyl azide (5.09 g, 16.45 mmol, 1.2 eq) in THF (40 mL). After 5 minutes the reaction was quenched with glacial acetic acid (3.65 mL) and warmed to room temperature. The mixture was evaporated to ~20 mL under reduced pressure, diluted with brine (300 mL) and extracted with DCM (3 x 300 mL). The combined organics were washed with 10% NaHCO₃ aq, dried over MgSO₄, filtered, evaporated and purified by chromatography (silica gel, 60-100% DCM in hexanes) to give 3.81 g (80 %) of a clear oil: $[\alpha]^{20}_D = +84.0^\circ$ (c 1, CDCl₃); IR (film) 2957, 2870, 2105, 1781, 1701, 1455, 1387, 1211, 1109, 702 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.2-7.4 (m, 5H), 4.99 (d, J = 8.7, 1H), 4.70 (m, 1H), 4.24, (M, 2H), 3.32 (dd, J = 3.3, 13.6, 1H), 2.87 (dd, J = 9.4, 13.5, 1H), 2.47 (m, 1H), 1.8-1.9 (m. 1H), 1.5-1.8 (m, 6H), 1.25-1.33 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 170.4, 152.9, 134.7, 129.4, 127.4, 66.4, 63.2, 55.4, 41.3, 37.5, 29.2, 28.8, 25.3, 25.1; HRMS (Cl+, NH₃) calc'd for C₁₇H₂₀N₄O₃: 346.1879, found 346.1879.

2S-azido- α -cyclopentylacetic acid (3)

To an ice cold solution of the oxazolidinone 2 (3.74 g, 11.4 mmol) in THF/H₂O (3/1, 120 mL) was added solid LiOH·H₂O (0.955 g, 22.8 mmol, 2 eq). After stirring for 1 hour at 0°C, NaHCO₃ aq. (0.5 M, 120 mL) was added and the THF was evaporated under reduced pressure. The aqueous mixture was washed with DCM (4 x 100 mL), acidified to pH 2 with 3M HCl and extracted with EtOAc (3 x 150 mL). The combined EtOAc layers were dried over Na₂SO₄, filtered and

evaporated to give 1.85 g (87 %) of a clear oil: $[\alpha]^{20}_D = -38.4^\circ$ (c 0.5, $CDCl_3$); IR (film) 2300-3500 br, 2953, 2103, 1717, 1233, 646, 631, 619 cm^{-1} ; 1H NMR (400 MHz, $CDCl_3$) δ 10.1 (br s, 1H), 3.73 (d, $J = 7.9$, 1H), 2.39 (m, 1H), 1.74-1.9 (m, 2H), 1.54-1.73 (m, 4H), 1.4-1.5 (m, 2H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 176.5, 65.7, 41.3, 29.3, 28.8, 25.3, 25.1; HRMS (CI+, NH_3) calc'd for $C_7H_{11}N_3O_2$: 187.1195, found 187.1189.

L- α -cyclopentylsarcosine (4)

To a solution of the azide 3 (1.29 g, 7.6 mmol) in 1,2-dichloroethane (20 mL) at room temperature was added a solution of bromodimethylborane (1.34 g, 11.1 mmol, 1.46 eq. in 35 mL 1,2 dichloroethane) dropwise over 1.5 hours. After stirring for 1 hour the reaction, EtOH (652 μ L, 11.1 mmol, 1.46 eq.) was added, stirred for an additional 20 minutes and concentrated to ~20 mL under reduced pressure. This suspension was triturated with DCM (100 mL) and filtered to give 1.66 g (92 %) of an off white solid after drying under vacuum: $[\alpha]^{20}_D = +20.3^\circ$ (c 1, $MeOH$); IR (film) 2300-3250 br, 2955, 2350, 1736, 1557, 1460, 1208 cm^{-1} ; 1H NMR (400 MHz, CD_3OD) δ 3.93 (d, $J = 6.4$, 1H), 2.74 (s, 3H), 2.38 (m, 1H), 1.75-1.93 (m, 2H), 1.53-1.73 (m, 5H), 1.39-1.5 (m, 1H); ^{13}C NMR (100 MHz, CD_3OD) δ 170.6, 66.1, 41.6, 33.2, 30.2, 29.2, 26, 25.9; HRMS (CI+, NH_3) calc'd for $C_8H_{15}NO_2$: 158.1181, found 158.1185.

9-fluorenylmethyloxycarbonyl-L- α -cyclopentylsarcosine (Fmoc-CpSar-OH) (5)

To a solution of the aminoacid 4 (184 mg, 773 μ mol) in H_2O /dioxane (1/1, 20 mL), solid Na_2CO_3 (287 mg, 2.7 mmol, 3.5 eq) and 9-fluorenylmethylchloroformate (300 mg, 1.16 mmol, 1.5 eq.) were added. After stirring overnight at room temperature, more Na_2CO_3 (100 mg) was added and the reaction was complete after stirring for 1 hour. The reaction mixture was

diluted with H₂O (30 mL), extracted with EtOAc (2 x 30 mL), acidified to pH 2 with 3M HCl and extracted with EtOAc (3 x 30 mL). The combined organics were washed with brine (30 mL), dried over Na₂SO₄, filtered and evaporated to give 190 mg (95 %) of a white solid: [α]²⁰_D = -45° (c 1, CDCl₃); IR (film) 2250-3400 br, 2953, 1740, 1701, 1451, 1402, 1319, 1138, 758, 741 cm⁻¹; ¹H NMR (400 MHz, CDCl₃), 2 rotamers, δ 7.77-7.73 (m, 4H), 7.5-7.65 (m, 4H), 7.24-7.43 (m, 8H), 4.41-4.59 (m, 6H), 4.2-4.3 (m, 2H), 4.11-4.17 (m, 1H), 2.91, 2.89 (2s, 6H), 2.39, 2.23 (2m, 2H), 1.94, 1.83 (2m, 2H), 1.35-1.74 (m, 12H), 1.25, 1.01 (2m, 3H); ¹³C NMR (100 MHz, CDCl₃), 2 rotamers, δ 176.4, 176.3, 157.3, 156.2, 144.1, 144.0, 143.9, 143.9, 143.8, 141.5, 141.4, 141.4, 127.8, 127.7, 127.1, 125.0, 124.9, 120.0, 120.0, 67.9, 67.6, 63.4, 63.0, 47.4, 39.1, 39.0, 31.2, 31.0, 30.6, 29.8, 29.7, 25.6, 25.5, 24.9, 24.8; HRMS (CI+, NH₃) calc'd for C₂₃H₂₅NO₄: 380.1862, found 380.1866.

N-tButyloxycarbonyl-(4R)-4-[(E)-2-butenyl]-4,N-dimethyl-L-threonine allyl ester (Boc-MeBmt-OAll) (6)

To a solution of Boc-MeBmt-OH (97 mg, 322 μmol) in EtOH/H₂O (6/1, 3.5 mL), Cs₂CO₃ (110 mg, 338 μmol, 1.05 eq) was added, stirred for 30 minutes, evaporated and azeotroped with benzene (3 x 5 mL). The cesium salt was dissolved in DMF (1 mL) and allyl bromide (33.4 μL, 386 μmol, 1.2 eq) was added via syringe and the reaction was stirred overnight at room temperature. The reaction mixture was separated between H₂O and diethyl ether (30 mL each), washed with H₂O (30 mL), dried over Na₂SO₄, filtered, evaporated and purified by chromatography (silica gel, 10-25% EtOAc in hexanes) to give 107 mg (97 %) of a clear oil: [α]²⁰_D +0.7° (c 1, CDCl₃); IR (film) 3478 br, 2975, 2934, 1750, 1648, 1482, 1451, 1393, 1368, 1323, 1252, 1152, 968, 934, cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 5.93 (m, 1H), 5.4-5.53 (m, 2H), 5.35 (d, J = 17.2, 1H), 5.25 (d, J = 10.4, 1H), 4.5-4.85 (m, 3H), 3.75-4.0 (m, 2H), 2.99, 2.95 (2s, 3H), 2.28-2.46 (m, 1H), 1.88-2.03

(m, 1H), 1.67, (d, J = 5.0, 3H), 1.48, 1.45 (2s, 9H), 0.87 (d, J = 6.7, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 170.3, 157.2, 131.7, 129.1, 126.9, 118.3, 80.5, 75.5, 65.7, 63.3, 36.1, 35.8, 28.2, 17.9, 15.6; HRMS (CI+, NH_3) calc'd for $\text{C}_{18}\text{H}_{31}\text{NO}_5$: 342.2280, found 342.2264.

HNMeBmt-OAll (7)

To a solution of Boc-MeBmt-OAll 6 (76.6 mg, 0.22 mmol) in DCM (1 mL) at 0°C, trifluoroacetic acid (0.5 mL) was added dropwise. After stirring for 2 hours, the reaction was quenched into 10% NaHCO_3 aq. (30 mL), diluted with H_2O (10 mL) and the pH was adjusted to 9.5 with 1N NaOH. This solution was extracted with EtOAc (4 x 40 mL) and the combined organics were dried over Na_2SO_4 , filtered and evaporated to give 50.2 mg (90 %) of a crude oil.

Fmoc-CpSar-MeBmt-OAll (8)

To a solution of acid 5 (19 mg, 50 μmol , 0.97 eq) and the crude amine 7 (12.5 mg, 52 μmol) in DCM (300 μl), diisopropylethylamine (30 μL) was added followed by PyBrop (29 mg, 62.2 μmol , 1.2 eq) and the reaction was stirred overnight under nitrogen. The reaction mixture was purified by chromatography (silica, 10-20% EtOAc in hexanes to give 10.5 mg (35 %) of an oil: IR (film) ? cm^{-1} ; ^1H NMR (400 MHz, CDCl_3), multiple rotamers, δ 7.2-7.8 (m, 8H), 5.83-6 (m, 1H), 5.2-5.5 (m, 4H), 4.8-5.0 (m, 1H), 4.53-4.75 (m, 3H), 4.4-4.54 (m, 1H), 4.17-4.27 (m, 1H), 3.85-4.15 (m, 1.5H), 3.80 (d, J = 10.8, 0.5H), 3.15, 2.84, 2.67, 2.25 (4s, 6H), 2.57-2.67 (m, 0.5H), 2.26-2.4 (m, 1.5H), 1.73-2 (m, 2H), 1.4-1.7 (m, 7H), 1.15-1.35 (m, 3H), 0.72, 0.81, 0.96 (3d, J = 6.8, 3H), 0.5, 0.22 (m, 1H); LRMS (FAB+, NaI) calc'd for $\text{C}_{36}\text{H}_{46}\text{N}_2\text{O}_6$: 602, found 603, 625 ($\text{M}+\text{H}$, $\text{M}+\text{Na}$).

Fmoc-CpSar-MeBmt-OH (9)

Allyl ester 8 (8.5 mg, 14.1 μ mol) and 3,3-dimethyl-1,5-cyclohexanedione (13.9 mg, 99 μ mol, 5 eq) were dissolved in THF (1 mL). A crystal of tetrakis-triphenylphosphine palladium was added and the reaction was stirred under nitrogen at room temperature for 2 hours. The reaction mixture was evaporated under nitrogen and purified by repeated chromatography (silica gel, 0 to 1% HOAc in 50% EtOAc/Hexanes to 1%HOAc in EtOAc) to give 4.3 mg (54 %) of an oil: 1 H NMR (400 MHz, CDCl₃), multiple rotamers, δ 7.27-7.8 (m, 8H), 5.3-5.55 (m, 2H), 3.8-4.9 (m, 6.5H), 3.79 (d, J = 10.8, 0.5H), 3.15, 2.84, 2.67, 2.25 (4s, 6H), 2.5-2.67 (m, 0.5H), 2.25-2.4 (m, 1.5H), 1.35-2 (m, 7.5H), 1-1.35 (m, 6.5H), 0.72, 0.81, 0.96 (3d, J=6.8, 3H); LRMS (FAB+, NaI) calc'd for C₃₃H₄₂N₂O₆: 562, found 585 (M+Na).

Fmoc-CpSar-MeBmt-Abu-Sar-MeLeu-Val-MeLeu-Ala-D-Ala-MeLeu-MeLeu-valinol ester (10)

To a solution of acid 9 (4.2 mg, 7.5 μ mol) and amine (from deprotection of 4, chapter 4 part 1) (8.42 mg, μ mol, 1.0 eq.) and lutidine (10 μ L) in DCM (200 μ L), PyAop (5.7 mg, μ mol, 1.46 eq) was added and the reaction was stirred overnight under nitrogen. The mixture was purified by chromatography (silica gel, 0-20% acetone in EtOAc) to give 12.0 mg (99 %) of an oil: 1 H NMR (500 MHz, CDCl₃) many rotamers, possible mixture of diastereomers, fingerprint spectra in appendix 1. LRMS (FAB+, NaI) calc'd for C₈₇H₁₄₀N₁₂O₁₆: 1608, found 1609, 1631 (M+H, M+Na).

HNMe-CpSar-MeBmt-Abu-Sar-MeLeu-Val-MeLeu-Ala-D-Ala-MeLeu-MeLeu-OH (11)

The protected undecapeptide 10 (12 mg, 7.45 μ mol), DBU (12 μ L) and LiBr (9 mg) were dissolved in THF/H₂O (10/1, 330 μ L) and stirred for 6 hours at room

temperature. More DBU (12 μ L) and LiBr (9 mg) were added and the reaction was stirred overnight. After evaporation of the THF under nitrogen, MeOH (500 μ L) and a drop of HOAc were added and the solution was filtered through a LH-20 column (6 cm x 1 cm). Product containing fractions were evaporated, dissolved in phosphate buffer (pH 7) and extracted with DCM (4 x 15 mL). The combined organics were dried over Na_2SO_4 , filtered and evaporated to give 5.5 mg (59 %) of a glassy solid: LRMS (FAB+) calc'd for $\text{C}_{64}\text{H}_{115}\text{N}_{11}\text{O}_{13}$: 1245, found 1246 ($\text{M}+\text{H}$).

CpSar11-CsA (12)

A solution of the deprotected peptide 11 (5.5 mg, 4.4 μ mol), PyAop (23 mg, 44 μ mol, 10 eq) and 2,6-lutidine (23 μ L) in DCM (10 mL) was stirred for 48 h at RT. The reaction mixture was evaporated and the residue dissolved in MeCN and purified by reverse phase HPLC (Beckman ODS ultrasphere 5 μ 10 mm x 25 cm, 0.1% TFA/MeCN 50:50-> 10:90 in 25 min., 70°C) to afford the pure cyclic peptide (2.8 mg, 52 %) as a white solid: R_f 0.3 (EtOAc); $[\alpha]^{20}\text{D}$ -205° (c 0.1, CHCl_3); IR (film) 3050-3580 br, 3320, 2957, 2850, 1636, 1558, 1506, 1456, 1412, 1098 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ = 0.71 (d, J = 6.0 Hz, 3H, $\text{CH}_3\text{-C}(4^1)$), 0.80-1.10 (m, 33H, $\text{CH}_3\text{-C}(3^2)$, 2 $\text{CH}_3\text{-C}(4^4)$, 2 $\text{CH}_3\text{-C}(3^5)$, 2 $\text{CH}_3\text{-C}(4^6)$, 2 $\text{CH}_3\text{-C}(4^9)$, 2 $\text{CH}_3\text{-C}(4^{10})$), 1.25 (d, J = 6.0 Hz, 3H, $\text{CH}_3\text{-C}(2^8)$), 1.35 (d, J = 7.2 Hz, 3H, $\text{CH}_3\text{-C}(2^7)$), 1.10-1.80, 1.90-2.20 (m, 25H, H-C(4¹), H-C(5¹), 2H-C(3²), 2H-C(3⁴), H-C(4⁴), 2H-C(3⁶), H-C(4⁶), 2H-C(3⁹), H-C(4⁹), 2H-C(3¹⁰), H-C(4¹⁰), H-C(3¹¹), 4H-C(4¹¹), 4H-C(5¹¹), 1.62 (m, 3H, H-C(8¹))), 2.42 (m, 2H, H-C(5¹), H-C(3⁵)), 2.68 (s, 3H, $\text{CH}_3\text{-N}^{10}$), 2.70 (s, 3H, $\text{CH}_3\text{-N}^{11}$), 3.10 (s, 3H, $\text{CH}_3\text{-N}^4$), 3.11 (s, 3H, $\text{CH}_3\text{-N}^9$), 3.26 (s, 3H, $\text{CH}_3\text{-N}^6$), 3.40 (s, 3H, $\text{CH}_3\text{-N}^3$), 3.52 (s, 3H, $\text{CH}_3\text{-N}^1$), 3.20, 4.72 (d, J = 13.9 Hz, 2H, 2H-C(2³)), 3.80 (m, 1H, H-C(3¹)), 4.52 (m, 1H, H-C(2⁷)), 4.65 (m, 1H, H-C(2⁵)), 4.82 (m, 1H, H-C(2⁸)), 4.95-5.1 (m, 3H, H-C(2²), H-C(2⁶), H-C(2¹⁰)), 5.17

5

(d, $J = 11.2$ Hz, 1H, H-C(2¹¹)), 5.33 (m, 3H, H-C(6¹), H-C(7¹), H-C(2⁴)), 5.47 (d, $J = 6.2$ Hz, 1H, H-C(2¹)), 5.69 (dd, $J = 4.3, 10.9$ Hz, 1H, H-C(2⁹)), 7.18 (d, $J = 7.9$ Hz, 1H, H-N⁸), 7.46 (d, $J = 8.5$ Hz, 1H, H-N⁵), 7.69 (d, $J = 7.5$ Hz, 1H, H-N⁷), 7.99 (d, $J = 9.8$ Hz, 1H, H-N²).; LRMS (FAB+) calc'd for C₆₄H₁₁₃N₁₁O₁₂: 1227, found 1228 (M+H).

10
15
20
25

Example 3: Interaction of a Modified Cyclosporin A with a Modified Cyclophilin Induces Gene Activation Selectively in Cells Expressing the Modified Cyclophilin

This Example shows that the modified cyclosporin A, CpSar11-CsA, interacts specifically with a modified cyclophilin, CypAgtm, to induce cyclophilin-dependent gene activation.

A modified cyclophilin having the capability to interact with CpSar11-CsA was designed based on the crystal structure of cyclophilin, CypA, and CsA. The crystal structure of the CypA-CsA complex shows that residue 11 of CsA directly contacts Cyp, binding in a deep hydrophobic pocket in the active site of cyclophilin. (See Pflugl, G., et al, *Nature* 361:91-4 (1993) and Ke, H., et al, *Structure* 2:33-44 (1994).) It was reasoned that the addition of atoms at that site should significantly reduce the binding of CpSar11-CsA to CypA, presumably through steric interaction between the side chain of CpSar11 and CypA. To select possible receptors capable of binding CpSar11-CsA, computer models of complexes were generated between CpSar11-CsA and several CypA mutants. Based on these models, three mutations were selected in residues lining the binding pockets of CypA: one to remove the offending steric interaction (phenylalanine at amino acid position thirteen to glycine (F113G)), and two others (serine at amino acid position 99 to threonine (S99T) and cysteine at amino acid position 115 to methionine (C115M)) that improved the fit between the new receptor and ligand.

To determine CpSar11-CsA's binding characteristics, both the unmodified CypA and the modified CypA (S99T, F113G, C115M) (CypAgtm) was overexpressed in *E. coli* and purified according to standard techniques. The binding constants for CpSar11-CsA for each receptor was determined with a direct fluorescence binding assay according to the

procedure described in Belshaw, P.J., Schoepher, J.G., Lui, K-Q., Morrison, K.L. & Schreiber, S.L., *Angew Chem. Int. Ed. Engl.* 34:2129-32 (1995).

As shown in Table 1, CpSar11-CsA has little affinity for wild type CypA, yet binds CypAgtm with high affinity. Kds were determined using a direct fluorescence biding assay as previously described in Belshaw et al., supra.

Table I

Cyclophilin binding constants and NFAT-signaling inhibition for CpSar11-CsA

10

Assay	Binding Constant Kd	IC50 in Cellular NFAT-Signalling	
		>5 M	>400 nM
CypA wild type + NFAT-SEAP	>5 M		
CypAgtm + NFAT-SEAP	9 nM		25 nM

20

Since it is the composite surface of Cyp-CsA that binds to and thereby inhibits the phosphatase activity of Cn and as the modifications to both the receptor and ligand were expected to be buried in the complex, it was expected that these new receptor-ligand combinations would have the ability to inhibit calcineurin (Cn) and thus NFAT mediated gene activation. This hypothesis was confirmed by using a cellular assay in which NFAT-signaling was measured on a reporter gene, as described below.

CypA and mutants were sub-cloned from pGEX based expression vectors into pBJ5, a eukaryotic expression vector containing an N-terminal FLAG epitope tag. The signaling assay was performed as previously described in Belshaw, P.J., Spencer, D.M., Crabtree, G.R. & Schreiber, S.L., *Chemistry & Biology*, submitted (1996). Briefly 10^7

Jurkat cells were electroporated with NFAT-SEAP reporter plasmid (1 g) alone or in combination with a Cyp expression vector (5 g). After 20 hours, cells were stimulated in 96 well plates with phorbol ester (PMA)(50 ng/mL) and ionomycin (1 M), which mimics T cell activation and receptor signaling. Varying concentrations of CpSar11-CsA or of CsA were added to the cultures. Twenty-four hours later, cells were assayed for SEAP activity. The data for each transfection are presented as percent SEAP activity relative to the signal for [CpSar11-CsA]=0. Stimulation of these cells with phorbol ester (PMA) and ionomycin, which mimics the T cell receptor signaling, resulted in activation of NFAT via Cn.

The results of this assay, shown in Figure 1, indicate that CpSar11-CsA had little or no effect on reporter gene expression at concentrations up to 400 nM in cells expressing either endogenous cyclophilins alone or coexpressing a wild type cyclophilin. Yet, in cells expressing CypAgtm, CpSar11-CsA potently inhibited NFAT signaling as shown in Figure 1 and in Table 1, above. However, results were obtained with the following modified receptor-ligand pairs: a modified cyclophilin A, CypA (S99T, F113A), referred to herein as CypAat and the modified cyclosporin A, MeIle11-CsA. In fact, in this NFAT-signaling assay, it was found that although MeIle11-CsA potently inhibited NFAT signaling in cells expressing CypAat, MeIle11-CsA still inhibited NFAT signaling in cells transfected with the NFAT reporter gene alone (data not shown). Presumably this was due to formation of endogenous Cyp-MeIle11-CsA complexes that inhibited Cn. In this assay CsA has an IC50 of 15nM in cells transfected with NFAT-SEAP alone.

As can be seen from these results, the transfected cells were made conditionally sensitive to a drug, dependent on the expression of a dominant allele of its receptor protein.

25

Example 3: Other Exemplary Modified Cyclophilins and FK506 Molecules which Mediate Gene Activation by Selective Interaction with Modified Receptors

This Example describes additional modified cyclosporin and FK506 molecules which selectively interact with a modified cyclophilin and are capable of inducing NF-AT mediated gene transcription.

Altered cyclosporin molecules unable to bind to cyclophilins by virtue of a methyl group at the 11 position of the peptide ring or in another chemical strategy, a cyclopentyl CsA, were prepared. These molecules, generically referred to as CsA^{t-} after the fact that they are unable to combine with the wild-type cyclophilin to block the activity of calcineurin, are non-toxic and not immunosuppressive in normal cells or whole animals. An engineered cyclophilin molecule binding specifically to these modified cyclosporin and FK506 molecules was prepared. This modified cyclophilin contained mutations of F113G and S99T, which create a "hole" to accommodate the methyl or pentyl group of CsA^{t-}, thus permitting binding to the altered cyclosporins. We call the altered cyclophilins Cph^{t-} since they combine only with the non-toxic cyclosporin. A schematic of the binding of the CsA^{t-}/Cph^{t-} and the CsA/Cph complexes to the active site of calcineurin is shown in Figure 2.

In parallel studies altered FK506 molecules were made that have electrophilic additions "bumps" at the C9 position of FK506 generating 9-S-methoxy-FK506 (FK506^{t-}) that does not bind to endogenous FKBP, but does bind to FKBP12F36V (FKBPT^{t-}).

The affinity of the interaction between cyclosporin and the mutant cyclophilin was measured by binding of labeled protein. These were found to be about 7 nM with no detectable binding to the wildtype Cph. The half time of association and dissociation were similar for the bumped combinations and the wild type combinations. These experiments indicate that the bumped CsA should only be immunosuppressive in cells expressing the compensatory mutant Cph^{t-}. In parallel studies the binding of the 9-S-methoxy-FK506 to FKBP12 F36V was found to be 5 nM by Scatchard analysis of the binding of radiolabeled protein to pure FKBPT^{t-}. On the other hand, FK506 binds to FKBP with a Kd of 0.3 nM in the same assay indicating that some loss of affinity is related to the "bump-hole" combination, which could be optimized by introducing specific mutations and selecting for FKBP molecules having a higher affinity for the bumped FK506.

As illustrated in Figure 3, the bumped cyclosporin does not effect signaling by the antigen receptor. This was shown by incubating human peripheral mononuclear cells from blood donors with anti CD3 and CD28 in the presence of CsA and CsAt- from 0 to 1000 nM. At 48 hours cells were assayed for DNA synthesis by 3 [H] thymidine incorporation.

5

To determine if the Cph^{t-} would confer selective sensitivity to CsAt- to cells expressing it, Jurkat cells were transfected with the cyclophilin containing the compensatory mutation and tested for NF-AT-dependent transcription. As shown in Figure 4, CsAt^{t-} produced a complete blockage of signaling in cells transfected with Cph^{t-} but not Cph. Similarly, the bumped FK506 (9-methoxy FK506) has no effect on signaling unless cells are transfected with a FKBP containing the compensatory mutation that allows binding of the bumped FK506.

10

Example 4: Transgenic Mice Sensitive to the Immunosuppressive and Tolerogenic Effects of Cyclosporin A and/or FK506, but Resistant to its Toxic Effects

One prediction of the theory that calcineurin is the sole target of the immunosuppressive as well as the toxic side effects of both the cyclosporin A/CpH and FK506/FKBP complexes is that if the formation of these complexes could be directed solely to lymphoid tissue they would be non-toxic for other organs. To do this transgenic mice that express Cph^{t-} only in 5 T cells and B cells. For expression in T cells, the gene encoding the modified cyclophilin can be operably linked to the CD4 promoter/enhancer. This will result in expression in all T cells from the double positive stage in the thymus to mature peripheral lymphocytes. For expression in B cells, the gene encoding the cyclophilin molecule can be operably linked to the immunoglobulin Eu promoter/enhancer. Both of these promoters have been 10 used frequently in the art to obtain T or B cell specific expression, respectively. The transgenic mice can be prepared according to methods known in the art.

To test the animals for sensitivity to CsA^{t-}, peripheral leukocytes can be isolated from these animals and the ability of the transgenic lymphocytes to proliferate in response to irradiated murine fibroblasts from a strain of mouse having an MHC background that 15 gives maximum stimulation with the FYB strain can be tested.

If, as predicted, lymphocyte proliferation is completely inhibited by CsAt-, it can be determined if CsA^{t-} can suppress rejection of tissue grafts. This can be done, e.g., by comparing the ability of CsA and CsA^{t-} to block the immune responses to transplanted skin grafts. Groups of 20 mice can be treated with doses of each drug ranging from those 20 required to inhibit 25 to 99% of calcineurin activity assayed by NF-AT dephosphorylation assay using extracts from peripheral blood lymphocytes. This is probably be in the range of 1 mg/kg/day to 10 mg/kg/day. No other immunosuppressive agent should be given and graft rejection can be tested at intervals after initiation of treatment and grafting. Toxic side effects can be assessed by observation for the CNS toxicity which is manifested as 25 ataxia and excessive activity. Renal toxic effects can be assessed by determining the concentration of BUN and creatinine. It is expected that this will show graft survival with fewer toxic side effects.

To test for the ability of CsA^{t-} to prevent the development of self tolerance one can treat the pregnant Cph^{t-} mice with doses of CsA^{t-} that lead to complete suppression of 30 graft rejection and determine if the newborn animals have undergone positive selection as judged by the development of single positive thymocytes and normal numbers of peripheral lymphocytes. Negative selection will be tested by several criteria. The most

stringent is the development of autoimmune phenomena after withdrawal of CsA^{t-}. If, as predicted, complete suppression of negative selection occurs, it is expected that the animals respond to their own tissue when the signaling pathway is restored by the terminating treatment with the drug. This will be accessed by examination of tissues such as the kidney, pancreas and others for inflammatory infiltrates, by the development of clones of autoreactive T cells judged by the failure of super antigen reactive cells to be deleted, and by the development of auto antibodies to classic self antigens such as DNA, and ribonuclear proteins.

To show that CsA^{t-} can suppress graft rejection, skin grafts from non-compatible mice can be implanted into Cph^{t-} transgenic mice, which can then be treated with CsA^{t-} and rejection of the graft will be assessed using well defined criteria. As previously shown for cyclosporin A, it is expected that CsA^{t-} will suppress rejection. To determine if long term total blockage of the antigen receptor signaling pathway will lead to tolerance to the transplanted tissue the animals can be treated for various lengths of time after transplantation with CsA^{t-}. It will then be tested if withdrawal of CsA^{t-} will allow continued suppression of graft rejection implying that the animals were made tolerant to the transplanted tissue.

To show that CsA^{t-} can prevent graft-vs-host disease, bone marrow can be taken from Cph^{t-} mice and transferred to irradiated MHC-mismatched mice and the mice observed for the development of graft-vs-host disease. Animals can be treated with CsA^{t-} for 1, 2, 4, or 8 weeks after transplantation with the dose necessary to inhibit: a) 50% or b) 99% of calcineurin activity in lymphocytes. In other experiment, purified stem cells from the Cph^{t-} mice can be used to do the transplantation.

The transgenic Cph^{t-} mice can also be used to confirm that complete blockage of the calcineurin/NF-AT pathway will prevent the development of autoimmune diabetes in NOD mice.

Cph^{t-} transgenic mice can be made either directly in NOD mice or in the FYB strain to facilitate breeding to the NOD mice as described above. Transgenic mice can be crossed with the NOD mice and followed for the expression of Cph^{t-} at levels approximating those of the endogenous Cph A gene. Once backcrossing is complete, the animals will be tested for the development of diabetes.

To test the effects of CsA^{t-} on the development of diabetes in the NOD mice, these can be administered CsA^{t-} at specific times during fetal life (p.c. day 14 to 21), after birth, 0- 3 weeks, 4-8 weeks, 4-12 weeks, and 4- 16 weeks. It is expected, based at least in part on previous results obtained, that CsA^{t-} will suppress the development of autoimmune diabetes. 5 Animals will be monitored for the symptoms of diabetes as known in the art and including: 1) determining the presence of auto antibodies to GAD, HSP70, CPH; 2) T cell activation and 3) islet inflammation and lymphoid infiltration.

The transgenic mice can also be used to show that long term suppression of the calcineurin/NF-AT pathway with CsA^{t-} can lead to tolerance and the prevention of 10 diabetes in the absence of continued CsA^{t-} treatment. The ability of CsA^{t-} to induce long term tolerance and prevention of inflammation in the islets of the NOD mice can be tested by withdrawing CsA^{t-} at various times after the initiation of treatment. The times until the development of symptoms will be measured as defined above. In addition animals can be monitored for the development of auto antibodies to GAD, CPH, and HSP70. 15 If the animals do not develop auto antibodies and do not develop disease after ceasing immunosuppression with CsA^{t-}, this will be indicative that the suppression of the Ca²⁺ /calcineurin pathway can lead to the development of tolerance and address the question of the underlying mechanism.

20 Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious to one skilled in the art that certain changes and modifications may be practiced within the scope of the appended claims.

APV007.25

- 64 -

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
5 (A) LENGTH: 348 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: cDNA

15 (ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 14..325

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

20	GGAATTCTTA ATA ATG TCC GTA CAA GTC GAA ACC ATC TCC CCA GGA GAC Met Ser Val Gln Val Glu Thr Ile Ser Pro Gly Asp 1 5 10	49
25	GGG CGC ACC TTC CCC AAG CGC GGC CAG ACC TGC GTG GTG CAC TAC ACC Gly Arg Thr Phe Pro Lys Arg Gly Gln Thr Cys Val Val His Tyr Thr 15 20 25	97
30	GGG ATG CTT GAA GAT GGA AAG AAA TTT GAT TCC TCC CGT GAC CGT AAC Gly Met Leu Glu Asp Gly Lys Lys Phe Asp Ser Ser Arg Asp Arg Asn 30 35 40	145
35	AAG CCC TTT AAG TTT ATG CTA GGC AAG CAG GAG GTG ATC CGA GGC TGG Lys Pro Phe Lys Phe Met Leu Gly Lys Gln Glu Val Ile Arg Gly Trp 45 50 55 60	193
40	GAA GAA GGG GTT GCC CAG ATG AGT GTG GGT CAG CGT GCC AAA CTG ACT Glu Glu Gly Val Ala Gln Met Ser Val Gly Gln Arg Ala Lys Leu Thr 65 70 75	241
45	ATA TCT CCA GAT TAT GCC TAT GGT GCC ACT GGG CAC CCA GGC ATC ATC Ile Ser Pro Asp Tyr Ala Tyr Gly Ala Thr Gly His Pro Gly Ile Ile 80 85 90	289
	CCA CCA CAT GCC ACT CTC GTC TTC GAT GTG GAG CTT CTAAAACTGG Pro Pro His Ala Thr Leu Val Phe Asp Val Glu Leu 95 100	335
	AATGACGGGA TCC	348

50

(2) INFORMATION FOR SEQ ID NO:2:

55 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7943 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: both
(D) TOPOLOGY: linear

60 (ii) MOLECULE TYPE: cDNA

65 (ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 80..7726

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

70	ACGGGGCTG AAGCGGCGGT ACCGGTGCTG GCGGCGGCAG CTGAGGCCTT GGCCGAAGCC	60
----	--	----

APV007.25

- 65 -

	GCAGCGAACCT CAGGGCAAG ATG CTT GGA ACC GGA CCT GCC GCC ACC ACC	112
	Met Leu Gly Thr Gly Pro Ala Ala Ala Thr Thr	
	1 5 10	
5	GCT GCC ACC ACA TCT AGC AAT GTG AGC GTC CTG CAG CAG TTT GCC AGT Ala Ala Thr Thr Ser Ser Asn Val Ser Val Leu Gln Gln Phe Ala Ser	160
	15 20 25	
10	GGC CTA AAG AGC CGG AAT GAG GAA ACC AGG GCC AAA GCC GCC AAG GAG Gly Leu Lys Ser Arg Asn Glu Glu Thr Arg Ala Lys Ala Ala Lys Glu	208
	30 35 40	
15	CTC CAG CAC TAT GTC ACC ATG GAA CTC CGA GAG ATG AGT CAA GAG GAG Leu Gln His Tyr Val Thr Met Glu Leu Arg Glu Met Ser Gln Glu Glu	256
	45 50 55	
20	TCT ACT CGC TTC TAT GAC CAA CTG AAC CAT CAC ATT TTT GAA TTG GTT Ser Thr Arg Phe Tyr Asp Gln Leu Asn His His Ile Phe Glu Leu Val	304
	60 65 70 75	
25	TCC AGC TCA GAT GCC AAT GAG AGG AAA GGT GGC ATC TTG GCC ATA GCT Ser Ser Ser Asp Ala Asn Glu Arg Lys Gly Gly Ile Leu Ala Ile Ala	352
	80 85 90	
30	AGC CTC ATA GGA GTG GAA GGT GGG AAT GCC ACC CGA ATT GGC AGA TTT Ser Leu Ile Gly Val Glu Gly Gly Asn Ala Thr Arg Ile Gly Arg Phe	400
	95 100 105	
35	GCC AAC TAT CTT CGG AAC CTC CTC CCC TCC AAT GAC CCA GTT GTC ATG Ala Asn Tyr Leu Arg Asn Leu Leu Pro Ser Asn Asp Pro Val Val Met	448
	110 115 120	
40	GAA ATG GCA TCC AAG GCC ATT GGC CGT CTT GCC ATG GCA GGG GAC ACT Glu Met Ala Ser Lys Ala Ile Gly Arg Leu Ala Met Ala Gly Asp Thr	496
	125 130 135	
45	TTT ACC GCT GAG TAC GTG GAA TTT GAG GTG AAG CGA GCA GCC CTG GAA TGG Phe Thr Ala Glu Tyr Val Glu Phe Glu Val Lys Arg Ala Leu Glu Trp	544
	140 145 150 155	
50	CTG GGT GCT GAC CGC AAT GAG GGC CGG AGA CAT GCA GCT GTC CTG GTT Leu Gly Ala Asp Arg Asn Glu Gly Arg Arg His Ala Ala Val Leu Val	592
	160 165 170	
55	CTC CGT GAG CTG GCC ATC AGC GTC CCT ACC TTC TTC TTC CAG CAA GTG Leu Arg Glu Leu Ala Ile Ser Val Pro Thr Phe Phe Phe Gln Gln Val	640
	175 180 185	
60	CAA CCC TTC TTT GAC AAC ATT TTT GTG GCC GTG TGG GAC CCC AAA CAG Gln Pro Phe Phe Asp Asn Ile Phe Val Ala Val Trp Asp Pro Lys Gln	688
	190 195 200	
65	GCC ATC CGT GAG GGA GCT GTA GCC CTT CGT GCC TGT CTG ATT CTC Ala Ile Arg Glu Gly Ala Val Ala Ala Leu Arg Ala Cys Leu Ile Leu	736
	205 210 215	
70	ACA ACC CAG CGT GAG CCG AAG GAG ATG CAG AAG CCT CAG TGG TAC AGG Thr Thr Gln Arg Glu Pro Lys Glu Met Gln Lys Pro Gln Trp Tyr Arg	784
	220 225 230 235	
75	CAC ACA TTT GAA GAA GCA GAG AAG GGA TTT GAT GAG ACC TTG GCC AAA His Thr Phe Glu Glu Ala Glu Lys Gly Phe Asp Glu Thr Leu Ala Lys	832
	240 245 250	
80	GAG AAG GGC ATG AAT CGG GAT GAT CGG ATC CAT GGA GCC TTG TTG ATC Glu Lys Gly Met Asn Arg Asp Asp Arg Ile His Gly Ala Leu Leu Ile	880
	255 260 265	
85	CTT AAC GAG CTG GTC CGA ATC AGC AGC ATG GAG GGA GAG CGT CTG AGA Leu Asn Glu Leu Val Arg Ile Ser Ser Met Glu Gly Glu Arg Leu Arg	928
	270 275 280	

	GAA GAA ATG GAA GAA ATC ACA CAG CAG CAG CTG GTA CAC GAC AAG TAC Glu Glu Met Glu Glu Ile Thr Gln Gln Gln Leu Val His Asp Lys Tyr 285 290 295	976
5	TGC AAA GAT CTC ATG GGC TTC GGA ACA AAA CCT CGT CAC ATT ACC CCC Cys Lys Asp Leu Met Gly Phe Gly Thr Lys Pro Arg His Ile Thr Pro 300 305 310 315	1024
10	TTC ACC AGT TTC CAG GCT GTA CAG CCC CAG CAG TCA AAT GCC TTG GTG Phe Thr Ser Phe Gln Ala Val Gln Pro Gln Gln Ser Asn Ala Leu Val 320 325 330	1072
15	GGG CTG CTG GGG TAC AGC TCT CAC CAA GGC CTC ATG GGA TTT GGG ACC Gly Leu Leu Gly Tyr Ser Ser His Gln Gly Leu Met Gly Phe Gly Thr 335 340 345	1120
20	TCC CCC AGT CCA GCT AAG TCC ACC CTG GTG GAG AGC CGG TGT TGC AGA Ser Pro Ser Pro Ala Lys Ser Thr Leu Val Glu Ser Arg Cys Cys Arg 350 355 360	1168
25	GAC TTG ATG GAG GAG AAA TTT GAT CAG GTG TGC CAG TGG GTG CTG AAA Asp Leu Met Glu Glu Lys Phe Asp Gln Val Cys Gln Trp Val Leu Lys 365 370 375	1216
30	TGC AGG AAT AGC AAG AAC TCG CTG ATC CAA ATG ACA ATC CTT AAT TTG Cys Arg Asn Ser Lys Asn Ser Leu Ile Gln Met Thr Ile Leu Asn Leu 380 385 390 395	1264
35	TTG CCC CGC TTG GCT GCA TTC CGA CCT TCT GCC TTC ACA GAT ACC CAG Leu Pro Arg Leu Ala Ala Phe Arg Pro Ser Ala Phe Thr Asp Thr Gln 400 405 410	1312
40	TAT CTC CAA GAT ACC ATG AAC CAT GTC CTA AGC TGT GTC AAG AAG GAG Tyr Leu Gln Asp Thr Met Asn His Val Leu Ser Cys Val Lys Lys Glu 415 420 425	1360
45	AAG GAA CGT ACA GCG GCC TTC CAA GCC CTG GGG CTA CTT TCT GTG GCT Lys Glu Arg Thr Ala Ala Phe Gln Ala Leu Gly Leu Leu Ser Val Ala 430 435 440	1408
50	GTG AGG TCT GAG TTT AAG GTC TAT TTG CCT CGC GTG CTG GAC ATC ATC Val Arg Ser Glu Phe Lys Val Tyr Leu Pro Arg Val Leu Asp Ile Ile 445 450 455	1456
55	CGA GCG GCC CTG CCC CCA AAG GAC TTC GCC CAT AAG AGG CAG AAG GCA Arg Ala Ala Leu Pro Pro Lys Asp Phe Ala His Lys Arg Gln Lys Ala 460 465 470 475	1504
60	ATG CAG GTG GAC GCC ACA GTC TTC ACT TGC ATC AGC ATG CTG GCT CGA Met Gln Val Asp Ala Thr Val Phe Thr Cys Ile Ser Met Leu Ala Arg 480 485 490	1552
65	GCA ATG GGG CCA GGC ATC CAG CAG GAT ATC AAG GAG CTG CTG GAG CCC Ala Met Gly Pro Gly Ile Gln Gln Asp Ile Lys Glu Leu Leu Glu Pro 495 500 505	1600
70	ATG CTG GCA GTG GGA CTA AGC CCT GCC CTC ACT GCA GTG CTC TAC GAC Met Leu Ala Val Gly Leu Ser Pro Ala Leu Thr Ala Val Leu Tyr Asp 510 515 520	1648
75	CTG AGC CGT CAG ATT CCA CAG CTA AAG AAG GAC ATT CAA GAT GGG CTA Leu Ser Arg Gln Ile Pro Gln Leu Lys Lys Asp Ile Gln Asp Gly Leu 525 530 535	1696
80	CTG AAA ATG CTG TCC CTG GTC CTT ATG CAC AAA CCC CTT CGC CAC CCA Leu Lys Met Leu Ser Leu Val Leu Met His Lys Pro Leu Arg His Pro 540 545 550 555	1744
85	GGC ATG CCC AAG GGC CTG GCC CAT CAG CTG GCC TCT CCT GGC CTC ACG Gly Met Pro Lys Gly Leu Ala His Gln Leu Ala Ser Pro Gly Leu Thr	1792

	560	565	570	
5	ACC CTC CCT GAG GCC AGC GAT GTG GGC AGC ATC ACT CTT GCC CTC CGA Thr Leu Pro Glu Ala Ser Asp Val Gly Ser Ile Thr Leu Ala Leu Arg 575	580	585	1840
10	ACG CTT GGC AGC TTT GAA TTT GAA GGC CAC TCT CTG ACC CAA TTT GTT Thr Leu Gly Ser Phe Glu Phe Gly His Ser Leu Thr Gln Phe Val 590	595	600	1888
15	CGC CAC TGT GCG GAT CAT TTC CTG AAC AGT GAG CAC AAG GAG ATC CGC Arg His Cys Ala Asp His Phe Leu Asn Ser Glu His Lys Glu Ile Arg 605	610	615	1936
20	ATG GAG GCT GCC CGC ACC TGC TCC CGC CTG CTC ACA CCC TCC ATC CAC Met Glu Ala Ala Arg Thr Cys Ser Arg Leu Leu Thr Pro Ser Ile His 620	625	630	1984
25	CTC ATC AGT GGC CAT GCT CAT GTG GTT AGC CAG ACC GCA GTG CAA GTG Leu Ile Ser Gly His Ala His Val Val Ser Gln Thr Ala Val Gln Val 640	645	650	2032
30	GTG GCA GAT GTG CTT AGC AAA CTG CTC GTA GTT GGG ATA ACA GAT CCT Val Ala Asp Val Leu Ser Lys Leu Leu Val Val Gly Ile Thr Asp Pro 655	660	665	2080
35	GAC CCT GAC ATT CGC TAC TGT GTC TTG GCG TCC CTG GAC GAG CGC TTT Asp Pro Asp Ile Arg Tyr Cys Val Leu Ala Ser Leu Asp Glu Arg Phe 670	675	680	2128
40	GAT GCA CAC CTG GCC CAG GCG GAG AAC TTG CAG GCC TTG TTT GTG GCT Asp Ala His Leu Ala Gln Ala Glu Asn Leu Gln Ala Leu Phe Val Ala 685	690	695	2176
45	CTG AAT GAC CAG GTG TTT GAG ATC CGG GAG CTG GCC ATC TGC ACT GTG Leu Asn Asp Gln Val Phe Glu Ile Arg Glu Leu Ala Ile Cys Thr Val 700	705	710	2224
50	GGC CGA CTC AGT AGC ATG AAC CCT GCC TTT GTC ATG CCT TTC CTG CGC Gly Arg Leu Ser Ser Met Asn Pro Ala Phe Val Met Pro Phe Leu Arg 720	725	730	2272
55	AAG ATG CTC ATC CAG ATT TTG ACA GAG TTG GAG CAC AGT GGG ATT GGA Lys Met Leu Ile Gln Ile Leu Thr Glu Leu Glu His Ser Gly Ile Gly 735	740	745	2320
60	AGA ATC AAA GAG CAG AGT GCC CGC ATG CTG GGG CAC CTG GTC TCC AAT Arg Ile Lys Glu Gln Ser Ala Arg Met Leu Gly His Leu Val Ser Asn 750	755	760	2368
65	GCC CCC CGA CTC ATC CGC CCC TAC ATG GAG CCT ATT CTG AAG GCA TTA Ala Pro Arg Leu Ile Arg Pro Tyr Met Glu Pro Ile Leu Lys Ala Leu 765	770	775	2416
70	ATT TTG AAA CTG AAA GAT CCA GAC CCT GAT CCA AAC CCA GGT GTG ATC Ile Leu Lys Leu Lys Asp Pro Asp Pro Asp Pro Asn Pro Gly Val Ile 780	785	790	2464
75	AAT AAT GTC CTG GCA ACA ATA GGA GAA TTG GCA CAG GTT AGT GGC CTG Asn Asn Val Leu Ala Thr Ile Gly Glu Leu Ala Gln Val Ser Gly Leu 800	805	810	2512
80	GAA ATG AGG AAA TGG GTT GAT GAA CTT TTT ATT ATC ATC ATG GAC ATG Glu Met Arg Lys Trp Val Asp Glu Leu Phe Ile Ile Met Asp Met 815	820	825	2560
85	CTC CAG GAT TCC TCT TTG TTG GCC AAA AGG CAG GTG GCT CTG TGG ACC Leu Gln Asp Ser Ser Leu Leu Ala Lys Arg Gln Val Ala Leu Trp Thr 830	835	840	2608
90	CTG GGA CAG TTG GTG GCC AGC ACT GGC TAT GTA GTA GAG CCC TAC AGG			2656

5	Leu Gly Gln Leu Val Ala Ser Thr Gly Tyr Val Val Glu Pro Tyr Arg 845 850 855	2704
10	AAG TAC CCT ACT TTG CTT GAG GTG CTA CTG AAT TTT CTG AAG ACT GAG Lys Tyr Pro Thr Leu Leu Glu Val Leu Leu Asn Phe Leu Lys Thr Glu 860 865 870 875	2752
15	CAG AAC CAG GGT ACA CGC AGA GAG GCC ATC CGT GTG TTA GGG CTT TTA Gln Asn Gln Gly Thr Arg Arg Glu Ala Ile Arg Val Leu Gly Leu Leu 880 885 890	2800
20	GGG GCT TTG GAT CCT TAC AAG CAC AAA GTG AAC ATT GGC ATG ATA GAC Gly Ala Leu Asp Pro Tyr Lys His Lys Val Asn Ile Gly Met Ile Asp 895 900 905	2848
25	CAG TCC CGG GAT GCC TCT GCT GTC AGC CTG TCA GAA TCC AAG TCA AGT Gln Ser Arg Asp Ala Ser Ala Val Ser Leu Ser Glu Ser Lys Ser Ser 910 915 920	2896
30	CAG GAT TCC TCT GAC TAT AGC ACT AGT GAA ATG CTG GTC AAC ATG GGA Gln Asp Ser Ser Asp Tyr Ser Thr Ser Glu Met Leu Val Asn Met Gly 925 930 935	2944
35	AAC TTG CCT CTG GAT GAG TTC TAC CCA GCT GTG TCC ATG GTG GCC CTG Asn Leu Pro Leu Asp Glu Phe Tyr Pro Ala Val Ser Met Val Ala Leu 940 945 950 955	2992
40	ATG CGG ATC TTC CGA GAC CAG TCA CTC TCT CAT CAT CAC ACC ATG GTT Met Arg Ile Phe Arg Asp Gln Ser Leu Ser His His His Thr Met Val 960 965 970	3040
45	GTC CAG GCC ATC ACC TTC ATC TTC AAG TCC CTG GGA CTC AAA TGT GTG Val Gln Ala Ile Thr Phe Ile Phe Lys Ser Leu Gly Leu Lys Cys Val 975 980 985	3088
50	CAG TTC CTG CCC CAG GTC ATG CCC ACG TTC CTT AAT GTC ATT CGA GTC Gln Phe Leu Pro Gln Val Met Pro Thr Phe Leu Asn Val Ile Arg Val 990 995 1000	3136
55	TGT GAT GGG GCC ATC CGG GAA TTT TTG TTC CAG CAG CTG GGA ATG TTG Cys Asp Gly Ala Ile Arg Glu Phe Leu Phe Gln Gln Leu Gly Met Leu 1005 1010 1015	3184
60	GTG TCC TTT GTG AAG AGC CAC ATC AGA CCT TAT ATG GAT GAA ATA GTC Val Ser Phe Val Lys Ser His Ile Arg Pro Tyr Met Asp Glu Ile Val 1020 1025 1030 1035	3232
65	ACC CTC ATG AGA GAA TTC TGG GTC ATG AAC ACC TCA ATT CAG AGC ACG Thr Leu Met Arg Glu Phe Trp Val Met Asn Thr Ser Ile Gln Ser Thr 1040 1045 1050	3280
70	ATC ATT CTT CTC ATT GAG CAA ATT GTG GTA GCT CTT GGG GGT GAA TTT Ile Ile Leu Leu Ile Glu Gln Ile Val Val Ala Leu Gly Gly Glu Phe 1055 1060 1065	3328
75	AAG CTC TAC CTG CCC CAG CTG ATC CCA CAC ATG CTG CGT GTC TTC ATG Lys Leu Tyr Leu Pro Gln Leu Ile Pro His Met Leu Arg Val Phe Met 1070 1075 1080	3376
80	CAT GAC AAC AGC CCA GGC CGC ATT GTC TCT ATC AAG TTA CTG GCT GCA His Asp Asn Ser Pro Gly Arg Ile Val Ser Ile Lys Leu Leu Ala Ala 1085 1090 1095	3424
85	ATC CAG CTG TTT GGC GCC AAC CTG GAT GAC TAC CTG CAT TTA CTG CTG Ile Gln Leu Phe Gly Ala Asn Leu Asp Asp Tyr Leu His Leu Leu Leu 1100 1105 1110 1115	3472
90	CCT CCT ATT GTT AAG TTG TTT GAT GCC CCT GAA GCT CCA CTG CCA TCT Pro Pro Ile Val Lys Leu Phe Asp Ala Pro Glu Ala Pro Leu Pro Ser 1120 1125 1130	

APV007.25

- 69 -

	CGA AAG GCA GCG CTA GAG ACT GTG GAC CGC CTG ACG GAG TCC CTG GAT Arg Lys Ala Ala Leu Glu Thr Val Asp Arg Leu Thr Glu Ser Leu Asp 1135 1140 1145	3520
5	TTC ACT GAC TAT GCC TCC CGG ATC ATT CAC CCT ATT GTT CGA ACA CTG Phe Thr Asp Tyr Ala Ser Arg Ile Ile His Pro Ile Val Arg Thr Leu 1150 1155 1160	3568
10	GAC CAG AGC CCA GAA CTG CGC TCC ACA GCC ATG GAC ACG CTG TCT TCA Asp Gln Ser Pro Glu Leu Arg Ser Thr Ala Met Asp Thr Leu Ser Ser 1165 1170 1175	3616
15	CTT GTT TTT CAG CTG GGG AAG AAG TAC CAA ATT TTC ATT CCA ATG GTG Leu Val Phe Gln Leu Gly Lys Lys Tyr Gln Ile Phe Ile Pro Met Val 1180 1185 1190 1195	3664
20	AAT AAA GTT CTG GTG CGA CAC CGA ATC AAT CAT CAG CGC TAT GAT GTG Asn Lys Val Leu Val Arg His Arg Ile Asn His Gln Arg Tyr Asp Val 1200 1205 1210	3712
25	CTC ATC TGC AGA ATT GTC AAG GGA TAC ACA CTT GCT GAT GAA GAG GAG Leu Ile Cys Arg Ile Val Lys Gly Tyr Thr Leu Ala Asp Glu Glu Glu 1215 1220 1225	3760
30	GAT CCT TTG ATT TAC CAG CAT CGG ATG CTT AGG AGT GGC CAA GGG GAT Asp Pro Leu Ile Tyr Gln His Arg Met Leu Arg Ser Gly Gln Gly Asp 1230 1235 1240	3808
35	GCA TTG GCT AGT GGA CCA GTG GAA ACA GGA CCC ATG AAG AAA CTG CAC Ala Leu Ala Ser Gly Pro Val Glu Thr Gly Pro Met Lys Lys Leu His 1245 1250 1255	3856
40	GTC AGC ACC ATC AAC CTC CAA AAG GCC TGG GGC GCT GCC AGG AGG GTC Val Ser Thr Ile Asn Leu Gln Lys Ala Trp Gly Ala Ala Arg Arg Val 1260 1265 1270 1275	3904
45	TCC AAA GAT GAC TGG CTG GAA TGG CTG AGA CGG CTG AGC CTG GAG CTG Ser Lys Asp Asp Trp Leu Glu Trp Leu Arg Arg Leu Ser Leu Glu Leu 1280 1285 1290	3952
50	CTG AAG GAC TCA TCA TCG CCC TCC CTG CGC TCC TGC TGG GCC CTG GCA Leu Lys Asp Ser Ser Pro Ser Leu Arg Ser Cys Trp Ala Leu Ala 1295 1300 1305	4000
55	CAG GCC TAC AAC CCG ATG GCC AGG GAT CTC TTC AAT GCT GCA TTT GTG Gln Ala Tyr Asn Pro Met Ala Arg Asp Leu Phe Asn Ala Ala Phe Val 1310 1315 1320	4048
60	TCC TGC TGG TCT GAA CTG AAT GAA GAT CAA CAG GAT GAG CTC ATC AGA Ser Cys Trp Ser Glu Leu Asn Glu Asp Gln Gln Asp Glu Leu Ile Arg 1325 1330 1335	4096
65	AGC ATC GAG TTG GCC CTC ACC TCA CAA GAC ATC GCT GAA GTC ACA CAG Ser Ile Glu Leu Ala Leu Thr Ser Gln Asp Ile Ala Glu Val Thr Gln 1340 1345 1350 1355	4144
70	ACC CTC TTA AAC TTG GCT GAA TTC ATG GAA CAC AGT GAC AAG GGC CCC Thr Leu Leu Asn Leu Ala Glu Phe Met Glu His Ser Asp Lys Gly Pro 1360 1365 1370	4192
	CTG CCA CTG AGA GAT GAC AAT GGC ATT GTT CTG CTG GGT GAG AGA GCT Leu Pro Leu Arg Asp Asp Asn Gly Ile Val Leu Leu Gly Glu Arg Ala 1375 1380 1385	4240
	GCC AAG TGC CGA GCA TAT GCC AAA GCA CTA CAC TAC AAA GAA CTG GAG Ala Lys Cys Arg Ala Tyr Ala Lys Ala Leu His Tyr Lys Glu Leu Glu 1390 1395 1400	4288
	TTC CAG AAA GGC CCC ACC CCT GCC ATT CTA GAA TCT CTC ATC AGC ATT Phe Gln Lys Gly Pro Thr Pro Ala Ile Leu Glu Ser Leu Ile Ser Ile 1405 1410 1415	4336

5	AAT AAT AAG CTA CAG CAG CCG GAG GCA GCG GCC GGA GTG TTA GAA TAT Asn Asn Lys Leu Gln Gln Pro Glu Ala Ala Ala Gly Val Leu Glu Tyr 1420 1425 1430 1435	4384
10	GCC ATG AAA CAC TTT GGA GAG CTG GAG ATC CAG GCT ACC TGG TAT GAG Ala Met Lys His Phe Gly Glu Leu Glu Ile Gln Ala Thr Trp Tyr Glu 1440 1445 1450	4432
15	AAA CTG CAC GAG TGG GAG GAT GCC CTT GTG GCC TAT GAC AAG AAA ATG Lys Leu His Glu Trp Glu Asp Ala Leu Val Ala Tyr Asp Lys Lys Met 1455 1460 1465	4480
20	GAC ACC AAC AAG GAC GAC CCA GAG CTG ATG CTG GGC CGC ATG CGC TGC Asp Thr Asn Lys Asp Asp Pro Glu Leu Met Leu Gly Arg Met Arg Cys 1470 1475 1480	4528
25	CTC GAG GCC TTG GGG GAA TGG GGT CAA CTC CAC CAG CAG TGC TGT GAA Leu Glu Ala Leu Gly Glu Trp Gly Gln Leu His Gln Gln Cys Cys Glu 1485 1490 1495	4576
30	AAG TGG ACC CTG GTT AAT GAT GAG ACC CAA GCC AAG ATG GCC CGG ATG Lys Trp Thr Leu Val Asn Asp Glu Thr Gln Ala Lys Met Ala Arg Met 1500 1505 1510 1515	4624
35	GCT GCT GCA GCT GCA TGG GGT TTA GGT CAG TGG GAC AGC ATG GAA GAA Ala Ala Ala Ala Trp Gly Leu Gly Gln Trp Asp Ser Met Glu Glu 1520 1525 1530	4672
40	TAC ACC TGT ATG ATC CCT CGG GAC ACC CAT GAT GGG GCA TTT TAT AGA Tyr Thr Cys Met Ile Pro Arg Asp Thr His Asp Gly Ala Phe Tyr Arg 1535 1540 1545	4720
45	GCT GTG CTG GCA CTG CAT CAG GAC CTC TTC TCC TTG GCA CAA CAG TGC Ala Val Leu Ala Leu His Gln Asp Leu Phe Ser Leu Ala Gln Gln Cys 1550 1555 1560	4768
50	ATT GAC AAG GCC AGG GAC CTG CTG GAT GCT GAA TTA ACT GCA ATG GCA Ile Asp Lys Ala Arg Asp Leu Leu Asp Ala Glu Leu Thr Ala Met Ala 1565 1570 1575	4816
55	GGA GAG AGT TAC AGT CGG GCA TAT GGG GCC ATG GTT TCT TGC CAC ATG Gly Glu Ser Tyr Ser Arg Ala Tyr Gly Ala Met Val Ser Cys His Met 1580 1585 1590 1595	4864
60	CTG TCC GAG CTG GAG GAG GTT ATC CAG TAC AAA CTT GTC CCC GAG CGA Leu Ser Glu Leu Glu Val Ile Gln Tyr Lys Leu Val Pro Glu Arg 1600 1605 1610	4912
65	CGA GAG ATC ATC CGC CAG ATC TGG TGG GAG AGA CTG CAG GGC TGC CAG Arg Glu Ile Ile Arg Gln Ile Trp Trp Glu Arg Leu Gln Gly Cys Gln 1615 1620 1625	4960
70	CGT ATC GTA GAG GAC TGG CAG AAA ATC CTT ATG GTG CGG TCC CTT GTG Arg Ile Val Glu Asp Trp Gln Lys Ile Leu Met Val Arg Ser Leu Val 1630 1635 1640	5008
75	GTC AGC CCT CAT GAA GAC ATG AGA ACC TGG CTC AAG TAT GCA AGC CTG Val Ser Pro His Glu Asp Met Arg Thr Trp Leu Lys Tyr Ala Ser Leu 1645 1650 1655	5056
80	TGC GGC AAG AGT GGC AGG CTG GCT CTT GCT CAT AAA ACT TTA GTG TTG Cys Gly Lys Ser Gly Arg Leu Ala Leu Ala His Lys Thr Leu Val Leu 1660 1665 1670 1675	5104
85	CTC CTG GGA GTT GAT CCG TCT CGG CAA CTT GAC CAT CCT CTG CCA ACA Leu Leu Gly Val Asp Pro Ser Arg Gln Leu Asp His Pro Leu Pro Thr 1680 1685 1690	5152
90	GTT CAC CCT CAG GTG ACC TAT GCC TAC ATG AAA AAC ATG TGG AAG AGT Val His Pro Gln Val Thr Tyr Ala Tyr Met Lys Asn Met Trp Lys Ser	5200

	1695	1700	1705	
	GCC CGC AAG ATC GAT GCC TTC CAG CAC ATG CAG CAT TTT GTC CAG ACC Ala Arg Lys Ile Asp Ala Phe Gln His Met Gln His Phe Val Gln Thr		5248	
5	1710 1715 1720			
	ATG CAG CAA CAG GCC CAG CAT GCC ATC GCT ACT GAG GAC CAG CAG CAT Met Gln Gln Ala Gln His Ala Ile Ala Thr Glu Asp Gln Gln His		5296	
	1725 1730 1735			
10	AAG CAG GAA CTG CAC AAG CTC ATG GCC CGA TGC TTC CTG AAA CTT GGA Lys Gln Glu Leu His Lys Leu Met Ala Arg Cys Phe Leu Lys Leu Gly		5344	
	1740 1745 1750 1755			
15	GAG TGG CAG CTG AAT CTA CAG GGC ATC AAT GAG AGC ACA ATC CCC AAA Glu Trp Gln Leu Asn Leu Gln Gly Ile Asn Glu Ser Thr Ile Pro Lys		5392	
	1760 1765 1770			
20	GTG CTG CAG TAC AGC GCC GCC ACA GAG CAC GAC CGC AGC TGG TAC Val Leu Gln Tyr Tyr Ser Ala Ala Thr Glu His Asp Arg Ser Trp Tyr		5440	
	1775 1780 1785			
25	AAG GCC TGG CAT GCG TGG GCA GTG ATG AAC TTC GAA GCT GTG CTA CAC Lys Ala Trp His Ala Trp Ala Val Met Asn Phe Glu Ala Val Leu His		5488	
	1790 1795 1800			
	TAC AAA CAT CAG AAC CAA GCC CGC GAT GAG AAG AAG AAA CTG CGT CAT Tyr Lys His Gln Asn Gln Ala Arg Asp Glu Lys Lys Lys Leu Arg His		5536	
	1805 1810 1815			
30	GCC AGC GGG GCC AAC ATC ACC AAC GCC ACC ACT GCC GCC ACC ACG GCC Ala Ser Gly Ala Asn Ile Thr Asn Ala Thr Thr Ala Ala Thr Thr Ala		5584	
	1820 1825 1830 1835			
35	GCC ACT GCC ACC ACC ACT GCC AGC ACC GAG GGC AGC AAC AGT GAG AGC Ala Thr Ala Thr Thr Ala Ser Thr Glu Gly Ser Asn Ser Glu Ser		5632	
	1840 1845 1850			
40	GAG GCC GAG AGC ACC GAG AAC AGC CCC ACC CCA TCG CCG CTG CAG AAG Glu Ala Glu Ser Thr Glu Asn Ser Pro Thr Pro Ser Pro Leu Gln Lys		5680	
	1855 1860 1865			
45	AAG GTC ACT GAG GAT CTG TCC AAA ACC CTC CTG ATG TAC ACG GTG CCT Lys Val Thr Glu Asp Leu Ser Lys Thr Leu Leu Met Tyr Thr Val Pro		5728	
	1870 1875 1880			
	GCC GTC CAG GGC TTC TTC CGT TCC ATC TCC TTG TCA CGA GGC AAC AAC Ala Val Gln Gly Phe Phe Arg Ser Ile Ser Leu Ser Arg Gly Asn Asn		5776	
	1885 1890 1895			
50	CTC CAG GAT ACA CTC AGA GTT CTC ACC TTA TGG TTT GAT TAT GGT CAC Leu Gln Asp Thr Leu Arg Val Leu Thr Leu Trp Phe Asp Tyr Gly His		5824	
	1900 1905 1910 1915			
55	TGG CCA GAT GTC AAT GAG GCC TTA GTG GAG GGG GTG AAA GCC ATC CAG Trp Pro Asp Val Asn Glu Ala Leu Val Glu Gly Val Lys Ala Ile Gln		5872	
	1920 1925 1930			
60	ATT GAT ACC TGG CTA CAG GTT ATA CCT CAG CTC ATT GCA AGA ATT GAT Ile Asp Thr Trp Leu Gln Val Ile Pro Gln Leu Ile Ala Arg Ile Asp		5920	
	1935 1940 1945			
65	ACG CCC AGA CCC TTG GTG GGA CGT CTC ATT CAC CAG CTT CTC ACA GAC Thr Pro Arg Pro Leu Val Gly Arg Leu Ile His Gln Leu Leu Thr Asp		5968	
	1950 1955 1960			
	ATT GGT CGG TAC CAC CCC CAG GCC CTC ATC TAC CCA CTG ACA GTG GCT Ile Gly Arg Tyr His Pro Gln Ala Leu Ile Tyr Pro Leu Thr Val Ala		6016	
	1965 1970 1975			
70	TCT AAG TCT ACC ACG ACA GCC CGG CAC AAT GCA GAC AAC AAG ATT CTG		6064	

APV007.25

- 72 -

	Ser Lys Ser Thr Thr Ala Arg His Asn Ala Ala Asn Lys Ile Leu		
	1980 1985 1990 1995		
5	AAG AAC ATG TGT GAG CAC AGC AAC ACC CTG GTC CAG CAG GCC ATG ATG Lys Asn Met Cys Glu His Ser Asn Thr Leu Val Gln Gln Ala Met Met	2000 2005 2010	6112
10	GTG AGC GAG GAG CTG ATC CGA GTG GCC ATC CTC TGG CAT GAG ATG TGG Val Ser Glu Glu Leu Ile Arg Val Ala Ile Leu Trp His Glu Met Trp	2015 2020 2025	6160
15	CAT GAA GGC CTG GAA GAG GCA TCT CGT TTG TAC TTT GGG GAA AGG AAC His Glu Gly Leu Glu Glu Ala Ser Arg Leu Tyr Phe Gly Glu Arg Asn	2030 2035 2040	6208
20	GTG AAA GGC ATG TTT GAG GTG CTG GAG CCC TTG CAT GCT ATG ATG GAA Val Lys Gly Met Phe Glu Val Leu Glu Pro Leu His Ala Met Met Glu	2045 2050 2055	6256
25	CGG GGC CCC CAG ACT CTG AAG GAA ACA TCC TTT AAT CAG GCC TAT GGT Arg Gly Pro Gln Thr Leu Lys Glu Thr Ser Phe Asn Gln Ala Tyr Gly	2060 2065 2070 2075	6304
30	CGA GAT TTA ATG GAG GCC CAA GAG TGG TGC AGG AAG TAC ATG AAA TCA Arg Asp Leu Met Glu Ala Gln Glu Trp Cys Arg Lys Tyr Met Lys Ser	2080 2085 2090	6352
35	GGG AAT GTC AAG GAC CTC ACC CAA GCC TGG GAC CTC TAT TAT CAT GTG Gly Asn Val Lys Asp Leu Thr Gln Ala Trp Asp Leu Tyr Tyr His Val	2095 2100 2105	6400
40	TTC CGA CGA ATC TCA AAG CAG CTG CCT CAG CTC ACA TCC TTA GAG CTG Phe Arg Arg Ile Ser Lys Gln Leu Pro Gln Leu Thr Ser Leu Glu Leu	2110 2115 2120	6448
45	CAA TAT GTT TCC CCA AAA CTT CTG ATG TGC CGG GAC CTT GAA TTG GCT Gln Tyr Val Ser Pro Lys Leu Leu Met Cys Arg Asp Leu Glu Leu Ala	2125 2130 2135	6496
50	GTG CCA GGA ACA TAT GAC CCC AAC CAG CCA ATC ATT CGC ATT CAG TCC Val Pro Gly Thr Tyr Asp Pro Asn Gln Pro Ile Ile Arg Ile Gln Ser	2140 2145 2150 2155	6544
55	ATA GCA CCG TCT TTG CAA GTC ATC ACA TCC AAG CAG AGG CCC CGG AAA Ile Ala Pro Ser Leu Gln Val Ile Thr Ser Lys Gln Arg Pro Arg Lys	2160 2165 2170	6592
60	TTG ACA CTT ATG GGC AGC AAC GGA CAT GAG TTT GTT TTC CTT CTA AAA Leu Thr Leu Met Gly Ser Asn Gly His Glu Phe Val Phe Leu Leu Lys	2175 2180 2185	6640
65	GGC CAT GAA GAT CTG CGC CAG GAT GAG CGT GTG ATG CAG CTC TTC GGC Gly His Glu Asp Leu Arg Gln Asp Glu Arg Val Met Gln Leu Phe Gly	2190 2195 2200	6688
70	CTG GTT AAC ACC CTT CTG GCC AAT GAC CCA ACA TCT CTT CGG AAA AAC Leu Val Asn Thr Leu Leu Ala Asn Asp Pro Thr Ser Leu Arg Lys Asn	2205 2210 2215	6736
	CTC AGC ATC CAG AGA TAC GCT GTC ATC CCT TTA TCG ACC AAC TCG GGC Leu Ser Ile Gln Arg Tyr Ala Val Ile Pro Leu Ser Thr Asn Ser Gly	2220 2225 2230 2235	6784
	CTC ATT GGC TGG GTT CCC CAC TGT GAC ACA CTG CAC GCC CTC ATC CGG Leu Ile Gly Trp Val Pro His Cys Asp Thr Leu His Ala Leu Ile Arg	2240 2245 2250	6832
	GAC TAC AGG GAG AAG AAG AAG ATC CTT CTC AAC ATC GAG CAT CGC ATC Asp Tyr Arg Glu Lys Lys Ile Leu Leu Asn Ile Glu His Arg Ile	2255 2260 2265	6880

APV007.25

- 73 -

	ATG TTG CGG ATG GCT CCG GAC TAT GAC CAC TTG ACT CTG ATG CAG AAG Met Leu Arg Met Ala Pro Asp Tyr Asp His Leu Thr Leu Met Gln Lys 2270 2275 2280	6928
5	GTG GAG GTG TTT GAG CAT GCC GTC AAT AAT ACA GCT GGG GAC GAC CTG Val Glu Val Phe Glu His Ala Val Asn Asn Thr Ala Gly Asp Asp Leu 2285 2290 2295	6976
10	GCC AAG CTG CTG TGG CTG AAA AGC CCC AGC TCC GAG GTG TGG TTT GAC Ala Lys Leu Leu Trp Leu Lys Ser Pro Ser Ser Glu Val Trp Phe Asp 2300 2305 2310 2315	7024
15	CGA AGA ACC AAT TAT ACC CGT TCT TTA GCG GTC ATG TCA ATG GTT GGG Arg Arg Thr Asn Tyr Thr Arg Ser Leu Ala Val Met Ser Met Val Gly 2320 2325 2330	7072
20	TAT ATT TTA GGC CTG GGA GAT AGA CAC CCA TCC AAC CTG ATG CTG GAC Tyr Ile Leu Gly Leu Gly Asp Arg His Pro Ser Asn Leu Met Leu Asp 2335 2340 2345	7120
25	CGT CTG AGT GGG AAG ATC CTG CAC ATT GAC TTT GGG GAC TGC TTT GAG Arg Leu Ser Gly Lys Ile Leu His Ile Asp Phe Gly Asp Cys Phe Glu 2350 2355 2360	7168
30	GTT GCT ATG ACC CGA GAG AAG TTT CCA GAG AAG ATT CCA TTT AGA CTA Val Ala Met Thr Arg Glu Lys Phe Pro Glu Lys Ile Pro Phe Arg Leu 2365 2370 2375	7216
35	ACA AGA ATG TTG ACC AAT GCT ATG GAG GTT ACA GGC CTG GAT GGC AAC Thr Arg Met Leu Thr Asn Ala Met Glu Val Thr Gly Leu Asp Gly Asn 2380 2385 2390 2395	7264
40	TAC AGA ATC ACA TGC CAC ACA GTG ATG GAG GTG CTG CGA GAG CAC AAG Tyr Arg Ile Thr Cys His Thr Val Met Glu Val Leu Arg Glu His Lys 2400 2405 2410	7312
45	GAC AGT GTC ATG GCC GTG CTG GAA GCC TTT GTC TAT GAC CCC TTG CTG Asp Ser Val Met Ala Val Leu Glu Ala Phe Val Tyr Asp Pro Leu Leu 2415 2420 2425	7360
50	AAC TGG AGG CTG ATG GAC ACA AAT ACC AAA GGC AAC AAG CGA TCC CGA Asn Trp Arg Leu Met Asp Thr Asn Thr Lys Gly Asn Lys Arg Ser Arg 2430 2435 2440	7408
55	ACG AGG ACG GAT TCC TAC TCT GCT GGC CAG TCA GTC GAA ATT TTG GAC Thr Arg Thr Asp Ser Tyr Ser Ala Gly Gln Ser Val Glu Ile Leu Asp 2445 2450 2455	7456
60	GGT GTG GAA CTT GGA GAG CCA GCC CAT AAG AAA ACG GGG ACC ACA GTG Gly Val Glu Leu Gly Glu Pro Ala His Lys Lys Thr Gly Thr Thr Val 2460 2465 2470 2475	7504
65	CCA GAA TCT ATT CAT TCT TTC ATT GGA GAC GGT TTG GTG AAA CCA GAG Pro Glu Ser Ile His Ser Phe Ile Gly Asp Gly Leu Val Lys Pro Glu 2480 2485 2490	7552
70	GCC CTA AAT AAG AAA GCT ATC CAG ATT ATT AAC AGG GTT CGA GAT AAG Ala Leu Asn Lys Ala Ile Gln Ile Ile Asn Arg Val Arg Asp Lys 2495 2500 2505	7600
	CTC ACT GGT CGG GAC TTC TCT CAT GAT GAC ACT TTG GAT GTT CCA ACG Leu Thr Gly Arg Asp Phe Ser His Asp Asp Thr Leu Asp Val Pro Thr 2510 2515 2520	7648
	CAA GTT GAG CTG CTC ATC AAA CAA GCG ACA TCC CAT GAA AAC CTC TGC Gln Val Glu Leu Leu Ile Lys Gln Ala Thr Ser His Glu Asn Leu Cys 2525 2530 2535	7696
	CAG TGC TAT ATT GGC TGG TGC CCT TTC TGG TAACTGGAGG CCCAGATGTG Gln Cys Tyr Ile Gly Trp Cys Pro Phe Trp 2540 2545	7746

5	CCCATCACGT TTTTCTGAG GCTTTGTAC TTTAGTAAAT GCTTCCACTA AACTGAAACC	7806
	ATGGTGAGAA AGTTTGACTT TGTTAAATAT TTTGAAATGT AAATGAAAAG AAGTACTGTA	7866
	TATTAAGT TGGTTGAAC CAACTTCTA GCTGCTGTTG AAGAATATAT TGTCAGAAC	7926
	ACAAGGCTTG ATTTGGT	7943

10 (2) INFORMATION FOR SEQ ID NO:3:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 723 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: both
 (D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: cDNA

25 (ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 15..509

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

30	GTGTACTATT AGCC ATG GTC AAC CCC ACC GTG TTC TTC GAC ATT GCC GTC Met Val Asn Pro Thr Val Phe Phe Asp Ile Ala Val 1 5 10	50
35	GAC GGC GAG CCC TTG GGC CGC GTC TCC TTT GAG CTG TTT GCA GAC AAG Asp Gly Glu Pro Leu Gly Arg Val Ser Phe Glu Leu Phe Ala Asp Lys 15 20 25	98
40	GTC CCA AAG ACA GCA GAA AAT TTT CGT GCT CTG AGC ACT GGA GAG AAA Val Pro Lys Thr Ala Glu Asn Phe Arg Ala Leu Ser Thr Gly Glu Lys 30 35 40	146
45	GGA TTT GGT TAT AAG GGT TCC TGC TTT CAC AGA ATT ATT CCA GGG TTT Gly Phe Gly Tyr Lys Gly Ser Cys Phe His Arg Ile Ile Pro Gly Phe 45 50 55 60	194
50	ATG TGT CAG GGT GGT GAC TTC ACA CGC CAT AAT GGC ACT GGT GGC AAG Met Cys Gln Gly Gly Asp Phe Thr Arg His Asn Gly Thr Gly Lys 65 70 75	242
55	TCC ATC TAT GGG GAG AAA TTT GAA GAT GAG AAC TTC ATC CTA AAG CAT Ser Ile Tyr Gly Glu Lys Phe Glu Asp Glu Asn Phe Ile Leu Lys His 80 85 90	290
60	ACG GGT CCT GGC ATC TTG TCC ATG GCA AAT GCT GGA CCC AAC ACA AAT Thr Gly Pro Gly Ile Leu Ser Met Ala Asn Ala Gly Pro Asn Thr Asn 95 100 105	338
65	GGT TCC CAG TTT TTC ATC TGC ACT GCC AAG ACT GAG TGG TTG GAT GGC Gly Ser Gln Phe Phe Ile Cys Thr Ala Lys Thr Glu Trp Leu Asp Gly 110 115 120	386
70	AAG CAT GTG GTG TTT GGC AAA GTG AAA GAA GGC ATG AAT ATT GTG GAG Lys His Val Val Phe Gly Lys Val Lys Glu Gly Met Asn Ile Val Glu 125 130 135 140	434
	GCC ATG GAG CGC TTT GGG TCC AGG AAT GGC AAG ACC AGC AAG AAG ATC Ala Met Glu Arg Phe Gly Ser Arg Asn Gly Lys Thr Ser Lys Lys Ile 145 150 155	482
	ACC ATT GCT GAC TGT GGA CAA CTC GAA TAAGTTGAC TTGTGTTTA Thr Ile Ala Asp Cys Gly Gln Leu Glu 160 165	529

APV007.25

- 75 -

TCTTAACCAC	CAGATCATTC	CTTCTGTAGC	TCAGGAGAGC	ACCCCTCCAC	CCCATTTGCT	589	
5	CGCAGTATCC	TAGAATCTTT	GTGCTCTCGC	TGCAGTTCCC	TTTGGGTTCC	ATGTTTCCT	649
TGTTCCCTCC	CATGCCTAGC	TGGATTGCAG	AGTTAAGTTT	ATGATTATGA	AATAAAAACT	709	
10	AAATAACAAT	TGTC				723	

WHAT IS CLAIMED IS:

1. A method for selectively inhibiting proliferation of a hematopoietic cell comprising contacting a hematopoietic cell which ectopically expresses a gene encoding a mutated macrolide binding protein (MBP) with a macrolide which selectively induces macrolide-dependent inhibition of proliferation of cells expressing the mutated MBP compared to cells expressing a wild-type form of the MBP, the mutated MBP having an altered macrolide-binding specificity relative to the wild-type form MBP.
5
- 10 2. A method for selectively inhibiting proliferation of a hematopoietic cell comprising
 - (i) causing, in the cell, the ectopic expression of an MBP gene encoding a mutated macrolide binding protein (MBP) having an altered macrolide-binding specificity relative to a wild-type form of the MBP, which mutated MBP retains the ability to cause macrolide-dependent inhibition of proliferation; and
 - (ii) contacting the cell with a macrolide which selectively binds to the altered MBP relative to the wild-type MBP and selectively induces macrolide-dependent inhibition of proliferation of cells expressing the mutated MBP relative to cells not expressing only the wild-type MBP.
15
- 20 3. The method of claim 2, wherein the MBP is selected from the group consisting of a FRAP, an FK506-binding protein, a cyclophilin and a calcineurin.
4. The method of claim 2, wherein the mutated MBP has a dissociation constant, K_d , at least one order of magnitude less than the K_d of the wild-type MBP.
5. The method of claim 2, wherein the mutated MBP has a dissociation constant, K_d , at least three orders of magnitude less than the K_d of the wild-type MBP.
25
6. The method of claim 2, wherein the MBP gene is present on an expression vector in the cell.
7. The method of claim 2, wherein the MBP gene is present in the cell as part of a viral expression construct.
- 30 8. The method of claim 2, wherein the MBP gene is a homologous recombinant in the cells genomic DNA.
9. The method of claim 2, wherein the macrolide is an analog of rapamycin, FK506 or cyclosporin.

10. The method of claim 2, wherein the MBP gene encodes a FRAP protein, and the macrolide is an analog of rapamycin.

11. The method of claim 2, wherein the MBP gene encodes an FK506 binding protein, and the macrolide is an analog of FK506 or rapamycin.

5 12. The method of claim 2, wherein the MBP gene encodes a calcineurin protein, and the macrolide is an analog of FK506 or cyclosporin.

13. The method of claim 2, wherein the MBP gene encodes a cyclophilin protein, and the macrolide is an analog of cyclosporin.

14. The method of claim 2, wherein the cell is a mammalian cell.

10 15. The method of claim 2, wherein the cell is a human cell.

16. A method for selectively inhibiting proliferation of a transplanted hematopoietic cell comprising

15 (i) transplanting, into an animal, hematopoietic cells which ectopically expresses a MBP gene encoding a mutated macrolide binding protein (MBP), the mutated MBP having an altered macrolide-binding specificity relative to the wild-type form MBP

(ii) administering to the animal an amount of a macrolide sufficient to inhibit proliferation of the transplanted cells, which macrolide selectively induces macrolide-dependent inhibition of proliferation of cells expressing the mutated MBP compared to cells expressing a wild-type form of the MBP.

20 17. The method of claim 16, wherein the MBP is selected from the group consisting of a FRAP, an FK506-binding protein, a cyclophilin and a calcineurin.

18. The method of claim 16, wherein the mutated MBP has a dissociation constant, K_d , at least one order of magnitude less than the K_d of the wild-type MBP.

25 19. The method of claim 16, wherein the mutated MBP has a dissociation constant, K_d , at least three orders of magnitude less than the K_d of the wild-type MBP.

20. The method of claim 16, wherein the MBP gene is present on an expression vector in the cell.

21. The method of claim 16, wherein the MBP gene is present in the cell as part of a 30 viral expression construct.

22. The method of claim 16, wherein the MBP gene is a homologous recombinant in the cells genomic DNA.

23. The method of claim 16, wherein the macrolide is an analog of rapamycin, FK506 or cyclosporin.

24. The method of claim 16, wherein the animal is a mammal.

25. The method of claim 24, wherein the animal is a human.

5 26. The method of claim 16, wherein the transplanted cells are autologous to the animal.

27. The method of claim 16 or 26, wherein the transplanted cells comprise transplanted bone marrow.

28. The method of claim 16 or 26, wherein the transplanted cells comprise hematopoietic stem cells.

10 29. The method of claim 16, wherein the ectopic expression of the MBP gene is transcriptionally regulated by a T-cell specific transcriptional regulatory sequence.

30. The method of claim 16, wherein the animal is in an immunosuppressed state.

31. A method for treating graft-versus-host disease in an animal by selectively inhibiting proliferation of transplanted hematopoietic cells, comprising

15 (i) prior to transplanting tissue containing hematopoietic cells, transducing at least a sub-population of hematopoietic cells of the tissue with a gene for ectopic expression of a mutated macrolide binding protein (MBP), the mutated MBP having an altered macrolide-binding specificity relative to the wild-type form MBP; and

20 (ii) subsequent to transplanting the hematopoietic cells, administering to the animal an amount of a macrolide sufficient to inhibit proliferation of the hematopoietic transplanted cells, which macrolide selectively induces macrolide-dependent inhibition of proliferation of the transplanted cells expressing the mutated MBP compared to endogenous cells of the animal.

25 32. An expression construct encoding a mutated macrolide binding protein (MBP) selected from the group consisting of FRAP, FKBP, cyclophilin and calcineurin, wherein the mutated MBP has an altered macrolide-binding specificity relative to the wild-type form MBP and, in the presence of a macrolide which binds the mutated MBP, induces macrolide-dependent inhibition of proliferation of a cell expressing

30 the mutated MBP.

33. A kit for selectively inhibiting proliferation of a hematopoietic cell, comprising

(i) an expression construct for ectopically expressing an MBP gene encoding a mutated macrolide binding protein (MBP) having an altered macrolide-binding

specificity relative to a wild-type form of the MBP, which mutated MBP retains the ability to cause macrolide-dependent inhibition of proliferation; and

5 (ii) a macrolide which selectively binds to the altered MBP relative to the wild-type MBP and selectively induces macrolide-dependent inhibition of proliferation of cells expressing the mutated MBP relative to cells not expressing only the wild-type MBP.

34. A method of promoting engraftment and hematopoietic activity of a hematopoietic stem cell from a donor, comprising:

10 (a) inserting nucleic acid encoding a modified macrolide binding protein specific for a modified macrolide into a hematopoietic stem cell to produce a transformed hematopoietic stem cell;

(b) introducing the transformed hematopoietic stem cell into a recipient mammal, such that the modified cellular receptor cyclophilin is expressed; and,

15 (c) administering an effective amount of the modified cyclosporin to said recipient mammal.

35. Hematopoietic stem cells transfected with the expression construct of claim 32.

36. A T cell transfected with an expression construct of claim 32.

ABSTRACT OF THE INVENTION

This invention is directed to a modified cyclosporin A and to a modified, 5 genetically engineered version of its receptor, cyclophilin. This invention is further directed to a method for treating host versus graft disease following blood marrow transplantation by transfecting stem cells so that after introduction into a patient the stem cells will express the modified cyclophilin, and, as necessary, administer the modified cyclosporin A to the patient.

FIGURE 1




Figure 2




Figure 3

100 90 80 70 60 50 40 30 20 10 0




Figure 4

